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A B S T R A C T
Background
Infection with enterotoxigenic Escherichia coli (ETEC) bacteria is a common cause of diarrhoea in adults and children in developing
countries and is a major cause of ’travellers’ diarrhoea’ in people visiting or returning from endemic regions. A killed whole cell vaccine
(Dukoral®), primarily designed and licensed to prevent cholera, has been recommended by some groups to prevent travellers’ diarrhoea
in people visiting endemic regions. This vaccine contains a recombinant B subunit of the cholera toxin that is antigenically similar to
the heat labile toxin of ETEC. This review aims to evaluate the clinical efficacy of this vaccine and other vaccines designed specifically
to protect people against diarrhoea caused by ETEC infection.
Objectives
To evaluate the efficacy, safety, and immunogenicity of vaccines for preventing ETEC diarrhoea.
Search methods
We searched the Cochrane Infectious Disease Group Specialized Register, the Cochrane Central Register of Controlled Trials (CEN-
TRAL), MEDLINE, EMBASE, LILACS, and http://clinicaltrials.gov up to December 2012.
Selection criteria
Randomized controlled trials (RCTs) and quasi-RCTs comparing use of vaccines to prevent ETEC with use of no intervention, a
control vaccine (either an inert vaccine or a vaccine normally given to prevent an unrelated infection), an alternative ETEC vaccine, or
a different dose or schedule of the same ETEC vaccine in healthy adults and children living in endemic regions, intending to travel to
endemic regions, or volunteering to receive an artificial challenge of ETEC bacteria.
Data collection and analysis
Two authors independently assessed each trial for eligibility and risk of bias. Two independent reviewers extracted data from the
included studies and analyzed the data using Review Manager (RevMan) software. We reported outcomes as risk ratios (RR) with 95%
confidence intervals (CI). We assessed the quality of the evidence using the GRADE approach.
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Main results
Twenty-four RCTs, including 53,247 participants, met the inclusion criteria. Four studies assessed the protective efficacy of oral cholera
vaccines when used to prevent diarrhoea due to ETEC and seven studies assessed the protective efficacy of ETEC-specific vaccines. Of
these 11 studies, seven studies presented efficacy data from field trials and four studies presented efficacy data from artificial challenge
studies. An additional 13 trials contributed safety and immunological data only.
Cholera vaccines
The currently available, oral cholera killed whole cell vaccine (Dukoral®) was evaluated for protection of people against ’travellers’
diarrhoea’ in a single RCT in people arriving in Mexico from the USA.We did not identify any statistically significant effects on ETEC
diarrhoea or all-cause diarrhoea (one trial, 502 participants, low quality evidence).
Two earlier trials, one undertaken in an endemic population in Bangladesh and one undertaken in people travelling from Finland to
Morocco, evaluated a precursor of this vaccine containing purified cholera toxin B subunit rather than the recombinant subunit in
Dukoral®. Short term protective efficacy against ETEC diarrhoea was demonstrated, lasting for around three months (RR 0.43, 95%
CI 0.26 to 0.71; two trials, 50,227 participants). This vaccine is no longer available.
ETEC vaccines
An ETEC-specific, killed whole cell vaccine, which also contains the recombinant cholera toxin B-subunit, was evaluated in people
travelling from the USA to Mexico or Guatemala, and from Austria to Latin America, Africa, or Asia. We did not identify any
statistically significant differences in ETEC-specific diarrhoea or all-cause diarrhoea (two trials, 799 participants), and the vaccine was
associated with increased vomiting (RR 2.0, 95% CI 1.16 to 3.45; nine trials, 1528 participants). The other ETEC-specific vaccines
in development have not yet demonstrated clinically important benefits.
Authors’ conclusions
There is currently insufficient evidence from RCTs to support the use of the oral cholera vaccine Dukoral® for protecting travellers
against ETECdiarrhoea. Further research is needed to develop safe and effective vaccines to provide both short and long-term protection
against ETEC diarrhoea.
P L A I N L A N G U A G E S U M M A R Y
Vaccines for preventing diarrhoea caused by enterotoxigenic Escherichia coli bacteria
Enterotoxigenic E. coli (ETEC) is a type of bacteria that can infect both children and adults, causing diarrhoea. In particular, it affects
people in developing countries. However, it is also a major cause of ’travellers’ diarrhoea’ in people visiting or returning from regions
where this infection is common. It is transmitted from person to person by eating or drinking unclean food or water. Typically it causes
watery diarrhoea, with abdominal pains and vomiting, that can last for several days. Vaccines are being considered as a way to prevent
diarrhoea caused by ETEC bacteria. ETEC bacteria share some similarities with the bacteria that cause cholera. In this review, we
examined the effectiveness of either vaccines designed to prevent cholera or vaccines designed specifically to prevent ETEC infection
for preventing ETEC diarrhoea. We compared these vaccines against the use of a control vaccine (either an inert vaccine or a vaccine
normally given to prevent an unrelated infection), no intervention, an alternative ETEC vaccine, or a different dose or schedule of the
same ETEC vaccine.
We examined the research published up to 07 December 2012. We included 24 randomized controlled trials and 53,247 participants
in this review. Four studies assessed the use of oral cholera vaccines to prevent diarrhoea caused by ETEC and eight trials assessed the
use of ETEC-specific vaccines to prevent diarrhoea. Seven studies presented data from field trials and four studies presented data from
studies where people were artificially infected with ETEC bacteria. Also, 13 trials gave safety and immunological data only.
There is currently insufficient evidence to support the use of the oral cholera vaccine Dukoral® to protect travellers against ETEC
diarrhoea. Based on a single trial in people travelling from the USA to Mexico, the oral cholera vaccine Dukoral® may have little or no
effect in preventing ETEC diarrhoea (one trial, 502 participants, low quality evidence). Two earlier trials, one undertaken in an endemic
population in Bangladesh and one undertaken in people travelling from Finland to Morocco, evaluated a precursor of the oral cholera
vaccine Dukoral®. Short term protection against ETEC diarrhoea was demonstrated, lasting for around three months (RR 0.43, 95%
CI 0.26 to 0.71; two trials, 50,227 participants). However, this vaccine is no longer available.
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An ETEC-specific, killed whole cell vaccine, which also contains the recombinant cholera toxin B-subunit, was evaluated in people
travelling from the USA to Mexico or Guatemala, and from Austria to Latin America, Africa, or Asia. There were no statistically
significant differences in ETEC-specific diarrhoea or all-cause diarrhoea (two trials, 799 participants) found and the vaccine was
associated with increased vomiting (RR 2.0, 95% CI 1.16 to 3.45; nine trials, 1528 participants). The other ETEC-specific vaccines in
development have not yet demonstrated clinically important benefits. Further research is needed to develop safe and effective vaccines
to provide both short and long-term protection against ETEC diarrhoea.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Cholera killed whole cells plus recombinant B-subunit vaccine for enterotoxigenic E. coli (ETEC) diarrhoea
Patient or population: People travelling from non-endemic settings
Settings: Endemic settings
Intervention: Cholera killed whole cells plus recombinant B-subunit vaccine (WC-rCTB Cholera)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Vaccine
ETEC diarrhoea 99 per 1000 120 per 1000
(72 to 198)
RR 0.93
(0.61 to 1.41)
502
(1 study)
⊕⊕©©
low1,2,3,4
Severe ETEC diarrhoea - - - (0 studies) -
All-cause diarrhoea 492 per 1000 512 per 1000
(428 to 610)
RR 1.04
(0.87 to 1.24)
502
(1 study)
⊕⊕©©
low1,4,5
Adverse events - - - 502
(1 study)
6
*The basis for the assumed risk (eg the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the
comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
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1 This single study was conducted in adults travelling from the USA to Mexico (Scerpella 1995). Although the paper does not clearly
describe the methods used to prevent selection bias, we have not downgraded the evidence as selection bias is probably unlikely in a
trial where everyone is healthy at enrolment.
2 Two older trials evaluated a prototype of this vaccine which contained purified cholera B-subunit rather than the recombinant subunit
contained in this vaccine. Although both trials found some evidence of benefit, the evidence may no longer be applicable due to changes
in both composition and dosing of the vaccine.
3 Downgraded by one for indirectness: in this study the vaccine was provided in two doses 10 days apart after the travellers had arrived
in Mexico. Most cases of ETEC diarrhoea occurred between doses or within seven days of administration of the second dose. The
authors conducted a subgroup analysis of only those participants who had diarrhoea > 7 days after the second dose, which excluded
75% of cases. We did not find a statistically significant difference in our analysis of this data.
4 Downgraded by one for imprecision: this trial was small and underpowered to reliably prove or exclude a clinically important effect with
the vaccine.
5 Downgraded by one for indirectness: in this study the vaccine was provided in two doses 10 days apart after the travellers had arrived
in Mexico. Further studies are required which assess administration prior to travel to a variety of destinations.
6 Scerpella 1995 reported no differences in the frequency of gastrointestinal symptoms, headaches, or febrile illnesses between
vaccinees, or placebo recipients but data were not presented.
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B A C K G R O U N D
Description of the condition
Enterotoxigenic Escherichia coli (ETEC) is the most common bac-
terial cause of diarrhoea in adults and children in developing coun-
tries (Qadri 2005;Walker 2007). The annual incidence of this dis-
ease is highest in young children and susceptibility to the disease
declines with age. Children born in endemic regions are likely to
experience two to three episodes of ETEC diarrhoea before their
fifth birthday (Wennerås 2004). The practical difficulties associ-
ated with making an accurate diagnosis of ETEC in low-resource
settings mean that its significance has often been underestimated
(Wennerås 2004; Qadri 2005). However, a review of microbiolog-
ical studies conducted in endemic regions between 1992 and 2000
found that ETEC was the causative organism in approximately
25% of all diarrhoeal episodes in children aged between one and
four years (Wennerås 2004). Many more children were shown to
carry the organism asymptomatically in their gut (Walker 2007).
A global burden of approximately 280 million clinical episodes
and 380,000 deaths annually are estimated (WHO 2009).
Person-to-person transmission of ETEC occurs via ingestion of
faecally-contaminated food or water. In developed countries where
sanitation standards are usually higher, ETEC infection is rare.
However, it remains a major cause of ’travellers’ diarrhoea’ which
occurs in people visiting or returning fromETEC-endemic regions
(Qadri 2005; DuPont 2008; Widermann 2009). Epidemics of
ETEC diarrhoea have also occurred during natural disasters, such
as floods, where there has been an acute deterioration in the quality
of drinking water and sanitation (Schwartz 2006; Harris 2008).
The clinical illness is characterized by a profuse watery diarrhoea
that lasts for several days and may be associated with abdominal
cramp,malaise, vomiting, and a low grade fever.Without adequate
treatment this can lead to dehydration. If people have a prolonged
infection or are infected again, this can lead to malnutrition or
growth inhibition in young children (Black 1984; Qadri 2005;
Qadri 2007).
Following ingestion, ETEC bacteria adhere to the lining of the gut
and secrete either one or both types of enterotoxins: the heat labile
toxin (LT) and the heat stable toxin (ST). These toxins induce
the hypersecretion of fluids and electrolytes, which cause the typ-
ical watery diarrhoea (Gill 1980). Different strains of ETEC can
be further characterized on the basis of the antigens expressed on
the cell surface: the colonization factor (CF), and the ’O’ and ’H’
antigens (Wolf 1997). Some of these antigens have been shown to
be important in inducing natural immunity and therefore repre-
sent key targets for vaccine development (Rao 2005; Svennerholm
2008). Over 100 different “O” antigens can be present on ETEC
and therefore have not been considered important for vaccine de-
velopment. Since both antitoxic and antibacterial antibodies are
important for protection, most vaccine formulations have been
based on the enterotoxins and CFs of ETEC (Svennerholm 1984;
Ahren 1998). Important antigens considered until now for vac-
cine development include the LT and CFs. Over 25 CFs that have
been characterized and most common CFs present on clinical iso-
lates include CFA/I, CS1, CS2, CS3, CS5, and CS6. These CFs
have been included as vaccine antigens on ETEC vaccines to date
(Harro 2011; Tobias 2011; Tobias 2012).
Improvements in public health and sanitation conditions repre-
sent the ideal solution to preventing transmission of ETEC and
other faecally-transmitted organisms. However, this can be diffi-
cult to achieve given the financial and logistical constraints in low-
resource regions. Thus prophylactic measures, including vaccines,
are being considered as alternative short-term strategies (Walker
2007).
Description of the intervention
Only one vaccine (Dukoral® produced by SBL Sweden) is cur-
rently available for the prevention of ETEC diarrhoea. This vac-
cine has been recommended to prevent ’travellers’ diarrhoea’ in
people visiting endemic regions from developed countries (Steffen
2005). This vaccine is primarily designed and licensed to pre-
vent diarrhoea due to Vibrio cholerae (cholera), but it contains a
recombinant B subunit of the cholera toxin that is antigenically
very similar to the LT of ETEC (Walker 2007). In an early clini-
cal trial, using a prototype of this vaccine which contained puri-
fied cholera B subunit rather than the recombinant form, signifi-
cant cross protection against ETEC diarrhoea was demonstrated
(Clemens 1988).
Many alternative vaccine candidates designed specifically to pro-
tect people against ETEC diarrhoea are now at various stages of
clinical development (Table 1). The vaccine candidates can be
broadly categorized in to two groups: inactivated vaccines con-
taining killed whole cells, purified CF antigens, or inactivated LT;
and live attenuated vaccines containing genetically modified, non-
pathogenic strains of ETEC, or alternative carrier bacteria express-
ing the important ETEC antigens (Svennerholm2008). Given the
number of antigenically different strains of ETEC, it is likely that a
vaccine formulation capable of providing broad protection would
need to contain a combination of the most commonly expressed
antigens (Walker 2007; Svennerholm 2008).
How the intervention might work
Epidemiological and experimental data suggest that natural im-
munity to ETEC does occur following natural infection and anti-
bodies against CF antigens and the B subunit of LT have been de-
tected (Qadri 2005; Rao 2005). Vaccine candidates aim to induce
similar immunity (without the associated clinical illness) and to
provide lasting protection against a broad range of the pathogenic
ETEC strains (Svennerholm 2008). Attempts have been made to
find immunological markers of protection, including toxin- or
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CF-specific immune responses, or both. CF-specific antibodies
have been used to determine ’take rates’ (the proportion of vac-
cinations that induce high antibody levels to vaccine) for ETEC
vaccines containing CFs as components (Wenneras 1999; Qadri
2003; Rao 2005). However, adequate and lasting protection can-
not be assumed without demonstrating reduced incidence of the
clinical illness in large, well conducted clinical trials.
The route of administration of a vaccine may influence both its
immunogenicity and acceptability. Oral vaccines have the poten-
tial to stimulate local immunity within themucosa of the gut, pre-
venting the colonization andmultiplication of the bacteria. ETEC
is transmitted through the faecal-oral route and vaccines designed
to be given orally have been developed (Holmgren 2005). Such
vaccines are easy to administer in all settings and have a reduced
risk of transmitting blood-borne infections.
Why it is important to do this review
Assessment of the level of mortality and morbidity associated with
ETEC diarrhoea and the extent of the global disease burden has
resulted in several initiatives to develop effective vaccines (Walker
2007). ETEC vaccine development is at an earlier stage than some
other vaccines (eg cholera vaccine) but data from phase II and
phase III trials in endemic areas and non-primed participants are
available and these need to be reviewed.
This review aims to evaluate the efficacy, safety, and immunogenic-
ity of current vaccine candidates tested in randomized controlled
trials (RCTs), including the oral cholera vaccine Dukoral®, when
used to protect against ETEC diarrhoea.
O B J E C T I V E S
To evaluate the efficacy, safety, and immunogenicity of vaccines
for preventing enterotoxigenic ETEC diarrhoea.
M E T H O D S
Criteria for considering studies for this review
Types of studies
RCTs and quasi-RCTs, for which the unit of randomization is the
individual participant or a cluster of participants.
Types of participants
Healthy adults and children living in endemic regions, intending
to travel to endemic regions, or receiving an artificial challenge.
Types of interventions
Intervention
Any vaccine being used to prevent ETEC diarrhoea. Studies eval-
uating vaccines which have not yet been evaluated for clinical out-
comes will be excluded.
Control
No intervention, a control vaccine (either an inert vaccine or a
vaccine normally given to prevent an unrelated infection), an alter-
native ETEC vaccine, or a different dose or schedule of the same
ETEC vaccine.
Types of outcome measures
Primary outcomes
Protective efficacy as measured against:
• Episodes of ETEC diarrhoea (any severity)
• Severe episodes of ETEC diarrhoea
Secondary outcomes
Protective efficacy as measured against:
• Episodes of all-cause diarrhoea
• Severe episodes of all-cause diarrhoea
Safety measured as:
• The number of adverse events, including systemic and local
reactions.
Immunological outcomes:
• Any immunological measure of response to vaccination, eg
an increase in CF, or toxin-specific, immune responses in serum/
plasma, or both, or an increase in antibody-secreting cell
responses in lymphocytes.
Search methods for identification of studies
We attempted to identify all relevant studies regardless of lan-
guage or publication status (published, unpublished, in press, or
in progress).
Electronic searches
Published studies
We searched the Cochrane Infectious Disease Group Special-
ized Register, the Cochrane Central Register of Controlled Trials
(CENTRAL), MEDLINE, EMBASE, LILACS and http://clini-
caltrials.gov/, using the search terms detailed in Table 2.
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Ongoing studies
We searched the metaRegister of Controlled Trials (mRCT) and
theWHOInternationalClinical TrialsRegistry Platform (ICTRP)
for ongoing trials using ’Enterotoxigenic’ and ’vaccin*’ as search
terms.
Searching other resources
Reference lists
We searched the reference lists of all included studies for additional
references relevant to this review.
Data collection and analysis
Selection of studies
Tanvir Ahmed (TA) and Taufiqur Bhuiyan (TB) independently
screened all citations and abstracts identified by the search strat-
egy to identify potentially eligible studies. We obtained full-text
articles of potentially eligible studies. TA and TB independently
assessed these articles for inclusion in the review using a pre-de-
signed eligibility form based on the inclusion criteria.
In the event that it was unclear whether a trial was eligible for the
review, we resolved any differences in opinion through discussion
with Firdausi Qadri (FQ). We excluded any studies that did not
meet the inclusion criteria and we documented the reasons for
exclusion.
Data extraction and management
For each included trial, TA and TB independently extracted in-
formation on the characteristics of the trial (study design, study
dates and duration, study location, setting, and source of fund-
ing), the participants recruited (the inclusion and exclusion cri-
teria), and the intervention (the type of vaccine, type of placebo,
dose, and immunization schedule), and listed the outcomes pre-
sented in the papers using a pre-tested data extraction form. For
all outcomes, we extracted the number of patients randomized to
each treatment group and the number of patients for whom an
outcome was available. For dichotomous outcomes, we extracted
the number of participants that experienced the event and the
number of patients in each treatment group. We extracted adverse
event data for each individual type of event wherever possible.
Where adverse events were reported for more than one dose, the
number of people reporting each side-effect after each dose was
recorded. Where trials reported the occurrence of adverse events
over time following a single dose, we recorded the proportion of
people affected during each time period. If the denominator or
total number of people affected for each time period was not clear,
then we only recorded the events that occurred in the first time
period (typically 72 hours) after each dose. Where data were miss-
ing or incomplete, we contacted the authors for clarification. In
cases of disagreement, we double-checked the data extraction and
we resolved any disagreements through discussion.
Assessment of risk of bias in included studies
Two authors (TA and TB) independently assessed the risk of bias
of each trial using ’The Cochrane Collaboration’s tool for assessing
the risk of bias’ (Higgins 2008). We followed the guidance to
assess whether steps were taken to reduce the risk of bias across six
domains: sequence generation; allocation concealment; blinding
(of participants, personnel, and outcome assessors); incomplete
outcome data; selective outcome reporting; and other sources of
bias.
For sequence generation and allocation concealment, we reported
the methods used. For blinding, we described who was blinded
and the blinding method. For incomplete outcome data, we re-
ported the percentage and proportion lost to follow-up in each
group. For selective outcome reporting, we stated any discrepan-
cies between the methods used and the results, in terms of the
outcomes measured or the outcomes reported. For other biases,
we described any other trial features that we thought could have
affected the trial result (eg if the trial was stopped early).
We categorized our judgements as either low, high, or unclear risk
of bias.We used this information to guide our interpretation of the
data. Where our judgement was unclear risk of bias, we attempted
to contact the trial authors for clarification and we resolved any
differences of opinion through discussion.
Measures of treatment effect
We expressed dichotomous outcomes using risk ratios (RR), and
presented with 95% confidence intervals (CI).
Unit of analysis issues
We ensured that the same patients were not included in the same
meta-analysis more than once, by grouping or splitting the data
in multi-arm trials as appropriate.
Dealing with missing data
If data from the trial reports were insufficient, unclear, or missing,
we attempted to contact the trial authors for additional informa-
tion. We aimed to carry out an intention-to-treat analysis. How-
ever if the duration of follow-up of all patients was not known, we
carried out a complete case analysis, in which we only included
patients for whom an outcome was available.
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Assessment of heterogeneity
We assessed heterogeneity between the trials by examining the
forest plot to check for overlapping CIs, by using the Chi2 test
for heterogeneity with a 10% level of significance, and by using
the I2 statistic with a value of 50% to represent moderate levels of
heterogeneity.
Assessment of reporting biases
We did not assess publication bias using funnel plots because the
number of trials per comparison were insufficient.
Data synthesis
We analyzed the data using Review Manager (RevMan).
We used the Mantel-Haenszel method to combine dichotomous
data. If there was no heterogeneity present, we used a fixed-effect
model. If there was moderate heterogeneity and it was still appro-
priate to combine studies, we used a random-effects model. When
it was deemed inappropriate to combine studies due to method-
ological or statistical heterogeneity, we presented the data in tables.
We stratified the primary analysis by vaccine type.
Subgroup analysis and investigation of heterogeneity
We planned to conduct subgroup analyses to investigate causes of
heterogeneity but the data were too limited.
Sensitivity analysis
As the number of trials per comparison were insufficient, we did
not conduct the pre-planned sensitivity analysis to assess the ro-
bustness of the results against risk of bias judgements.
Assessment of the quality of the evidence
We assessed the quality of evidence using the GRADE approach
(Guyatt 2008). The GRADE system considers ‘quality’ to be a
judgment of the extent to which we can be confident that the esti-
mates of effect are correct. The level of ‘quality’ is judged on a four-
point scale. Evidence from RCTs is initially graded as high and
downgraded by either one, two, or three levels after full considera-
tion of: any limitations in the design of the studies, the directness
(or applicability) of the evidence, the consistency and precision of
the results, and the possibility of publication bias.
R E S U L T S
Description of studies
Results of the search
We identified 55 potentially relevant articles for inclusion. We
assessed these articles using the pre-stated inclusion criteria (see
Figure 1).
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Figure 1. Study flow diagram.
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Included studies
We included 20 individual papers describing 24 trials which eval-
uated eight different vaccines. Of these, seven trials presented effi-
cacy data from field trials (Clemens 1988; Peltola 1991; Scerpella
1995; Wiedermann 2000; Sack 2007; Leyten 2005; Frech 2008),
and four trials presented efficacy data fromartificial challenge stud-
ies (Freedman 1998; Tacket 1999; McKenzie 2007; McKenzie
2008). A summary of themain characteristics of these trials is given
in Table 3. For further details see the Characteristics of included
studies tables. An additional 13 trials only contributed safety and
immunogenicity data.
Interventions
Three different killed whole cell vaccines were evaluated in efficacy
trials: the oral cholera vaccine with purified B-subunit (Cholera
WC-BS: Clemens 1988; Peltola 1991), the oral cholera vac-
cine with recombinant B-subunit (Cholera WC-rCTB: Scerpella
1995), and an ETEC vaccine with recombinant cholera B-subunit
(ETEC WC-rCTB: Wiedermann 2000; Sack 2007). Two live at-
tenuated vaccines have undergone evaluation of clinical efficacy:
one oral cholera vaccine (CVD 103-HgR: Leyten 2005) and one
ETEC-specific vaccine (PTL-003: McKenzie 2008). Two addi-
tional studies evaluated an LT subunit vaccine delivered by tran-
scutaneous patch (McKenzie 2007; Frech 2008) and two evalu-
ated passive immunization using hyperimmune anti-E. coli CFA
(Freedman 1998; Tacket 1999).
Populations
Only one vaccine was evaluated for use among an endemic pop-
ulation in a low income country and this vaccine is no longer
available (Cholera WC-BS: Clemens 1988). Five vaccines were
evaluated among travellers to endemic settings: Cholera WC-BS
(Peltola 1991). CholeraWC-rCTB (Scerpella 1995), ETECWC-
rCTB (Wiedermann 2000; Sack 2007), CVD 103-HgR (Leyten
2005), and the LT transcutaneous patch (Frech 2008). The re-
maining three vaccines were evaluated among volunteers in artif-
ical challenge studies.
Outcomes
Ten trials reported episodes of ETEC diarrhoea, six reported on
severe ETEC diarrhoea, and ten reported on all-cause diarrhoea.
The definitions of these outcomes varied between trials and we
have presented these in Table 4.
Excluded studies
We excluded 35 studies and we listed the reasons for exclusion in
the Characteristics of excluded studies table.
Risk of bias in included studies
We summarized the risk of bias assessments in Figure 2.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Efficacy studies
We judged five natural challenge studies to have adequately de-
scribed allocation concealment and we considered them to be at
low risk for selectionbias (Clemens 1988; Peltola1991; Sack 2007;
Leyten 2005; Frech 2008). In two natural challenge studies we
judged the risk of bias to be unclear (Scerpella 1995;Wiedermann
2000). Of the five artificial challenge studies, only one adequately
described a method of allocation concealment (Freedman 1998).
Safety and immunogenicity only studies
We judged 11 of the 13 safety and immunogenicity studies at low
risk of selection bias.
Blinding
Efficacy studies
We found that blinding of participants and study personnel
was clearly described in eight out of 11 efficacy trials (Clemens
1988; Peltola 1991; Scerpella 1995; Freedman 1998; Tacket 1999;
Leyten 2005; Sack 2007; Frech 2008), and was unclear in three.
Outcome assessors were blinded to treatment allocation in six trials
(Clemens 1988; Peltola 1991; Freedman 1998; Leyten 2005; Sack
2007; Frech 2008), and was unclear in five trials (Scerpella 1995;
Tacket 1999; Wiedermann 2000; McKenzie 2007; McKenzie
2008).
Safety and immunogenicity studies
Most studies (11 out of 13) used placebos which were identical
in appearance to the vaccine. We considered these studies to be at
low risk of bias for safety outcomes. In two studies assessors were
not blinded to make a judgement and so we classified these studies
at ’unclear’ risk of bias (Jertborn 1998; Jertborn 2001).
Incomplete outcome data
Efficacy studies
Seven efficacy trials had low losses to follow-up and we considered
these trials at low risk of attrition bias (Scerpella 1995; Freedman
1998; Tacket 1999; Leyten 2005; McKenzie 2007; Sack 2007;
McKenzie 2008). We found that three trials had high losses to
follow-up (Peltola 1991; Wiedermann 2000; Frech 2008) and we
judged these trials at high risk of attrition bias. One trial was un-
clear about the number of participants lost to follow-up (Clemens
1988).
Safety and immunogenicity studies
Eleven studies out of 13 reported minimal losses to follow-up. We
considered these trials at low risk of bias. Two studies had high
losses to follow-up and we judged these trials at high risk of bias
(Cohen 2000 (Study 2); Savarino 2002).
Selective reporting
We found no evidence of selective reporting bias in any of the
included studies.
Other potential sources of bias
We found no evidence of other potential sources of bias in the
trials.
Effects of interventions
See: Summary of findings for the main comparison Cholera
WC-rCTB vaccine for preventing enterotoxigenic E. coli (ETEC)
diarrhoea
Cholera killed whole cell vaccines versus placebo
Two oral vaccines containing killed whole cells of V. cholerae have
been evaluated. The first contained 1 mg of purified cholera B-
subunit (Cholera WC-BS). This vaccine was further developed
with a recombinant cholera B-subunit and is commercially avail-
able (Cholera WC-rBS).
Analysis 1: Cholera killed whole cells plus purified B-subunit
(Cholera WC-BS)
Clinical efficacy
In Bangladesh, in a passive surveillance study in a community en-
demic with ETEC diarrhoea, Clemens 1988 found that the oral
Cholera WC-BS vaccine provided short-term protection against
LT-ETEC diarrhoea at three months’ follow-up compared to the
same whole cell vaccine without the B-subunit (RR 0.33, 95% CI
0.13 to 0.84; one trial, 49,612 participants, Analysis 1.1). How-
ever, only 24 episodes of ETEC diarrhoea were reported in this
study (18 in the placebo group versus six in the vaccine group).
Eight episodes of severe ETEC diarrhoea were reported (seven in
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the placebo group versus one in the vaccine group) and this re-
sult was not statistically significant (one trial, 49,612 participants,
Analysis 1.2). No protective efficacy was demonstrated at later
time points.
One additional trial evaluated the same vaccine given to people
intending to travel from Europe to Morocco (Peltola 1991). The
authors found a statistically significant reduction in ETEC diar-
rhoea (RR 0.48, 95% CI 0.26 to 0.90; one trial, 615 participants,
Analysis 1.1) and all-cause diarrhoea (RR 0.77, 95% CI 0.59 to
1.00; one trial, 615 participants, Analysis 1.3).
Safety
Safety data were only available from 508 participants in Peltola
1991. ’Gastrointestinal symptoms’ were higher in those receiving
the placebo than the vaccine during the first three days after vacci-
nation (P = 0.03, Analysis 1.4). No other significant reactogenicity
was observed.
Immunological response
The studies did not report on the outcome of immunological
response.
Analysis 2: Cholera killed whole cells plus recombinant B-
subunit (Cholera WC-rCTB; Dukoral®)
Clinical efficacy
The currently available oral Cholera WC-rCTB vaccine was eval-
uated in a single RCT in people arriving in Mexico from the USA
(Scerpella 1995). There were no statistically significant differences
in episodes of either ETEC-specific diarrhoea or all-cause diar-
rhoea between those receiving vaccine and placebo (one trial, 502
participants, Analysis 2.1; Analysis 2.2). However, in this trial the
vaccine was only administered after arrival in Mexico and most
episodes of diarrhoea occurred before completion of the two dose
regimen or within 7 days of the second dose.
The authors of this paper considered that adequate protection
would not be attained until seven days after the second dose. They
reported a 50% protective effect in a subgroup analysis of cases
occurring after this timepoint (95% CI 14 to 71%, authors’ own
figures). However, it should be noted that this subgroup analysis
excluded 75% of the observed cases of ETEC diarrhoea. Only 19
episodes of ETEC diarrhoea were included (12 with placebo and
seven with vaccine), and our re-analysis of this data suggested that
this difference was not statistically significant (Analysis 2.3).
Safety
Scerpella 1995 reported that there were no differences in the fre-
quency of gastrointestinal symptoms, headache, or febrile illnesses
between people that received either the vaccine or placebo, but
data were not presented.
Immunological response
Toxin-specific IgG antibody (TSA) responses were available from
281 participants. A greater than four-fold increase was observed in
87% of the participants who received Cholera WC-rCTB vaccine
compared to 8% in controls (RR 10.54, 95% CI 6.11 to 18.20;
one trial, 281 participants, Analysis 2.4).
ETEC killed whole cell vaccines versus placebo
Analysis 3: ETEC killed whole cells plus recombinant cholera
B-subunit (ETEC WC-rCTB)
Clinical efficacy
Two studies have evaluated this oral ETEC vaccine (ETEC WC-
rCTB); in people travelling from theUSA toMexico orGuatemala
(Sack 2007), and from Austria to one of 44 different countries in
Latin America, Africa, or Asia (Wiedermann 2000). There were
no statistically significant differences in ETEC-specific diarrhoea,
or all-cause diarrhoea (two trials, 799 participants, Analysis 3.1;
Analysis 3.3).
In Sack 2007 a small number of severe ETEC episodes are recorded
(two in the vaccine group and nine in the placebo group), and this
difference approached statistical significance (RR 0.23, 95% CI
0.05 to 1.05; one trial, 671 participants, Analysis 3.2).
Safety
A total of 1695 participants have received ETEC WC-rCTB or
placebo in 11 RCTs. Vomiting was the only symptom significantly
more common in those receiving the vaccine compared to placebo
(RR 2.0, 95% CI 1.16 to 3.45; nine trials, 1528 participants,
Analysis 3.4).
Immunological response
CFA/I-specific antibody response:
Anti-CFA/I antibody responses were evaluated in 880 participants
in 12 RCTs. CFA/I-specific IgA antibody responses were evaluated
in serum, plasma, or antibody secreting cells (ASCs). They were
found to be statistically higher in the vaccine group compared
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to controls (RR 6.78, 95% CI 5.12 to 8.98, P < 0.00001; 12
trials, 880 participants, Analysis 3.5). In individual studies, the
proportion of participants with a greater than two-fold increase
following vaccination ranged from: 26% to 94% in adults; 96%
to 100% in children aged between 6 to 12 years; 73% to 95% in
children aged between 18 months to 5 years; and 59% to 61% in
infants aged between 6 to 18 months (Table 5).
CF-specific IgA antibody responses were also reported to anti-CS1
(10 trials), anti-CS2 (10 trials), anti-CS3 (one study), and anti-
CS4 (eight trials). These data are summarized in Table 5.
Toxin-specific antibody response:
Either CT or LT toxin-specific IgA antibody responses were eval-
uated in a total of 1228 participants in 13 RCTs. In individual
studies, the percentage of participants with > two-fold increases in
toxin-specific antibodies ranged from 50% to 100% in those re-
ceiving the vaccine compared to 0% to 33% in controls (RR 5.03,
95% CI 4.25 to 5.96, P < 0.00001; 13 trials, 1228 participants,
Analysis 3.6).
Live attenuated vaccines versus placebo
Two live attenuated vaccines have been evaluated in placebo con-
trolled trials: the oral cholera vaccine CVD 103-HgR in a natural
challenge study in travellers (Leyten 2005) and the oral ETEC
vaccine PTL-003 in a small artificial challenge study (McKenzie
2008).
Analysis 4: Live attenuated cholera vaccine (CVD 103-HgR)
Clinical efficacy
Leyten 2005 evaluated CVD103-HgR, a live oral cholera vaccine,
in Dutch volunteers intending to travel to Indonesia, Thailand,
the Indian subcontinent, or West Africa. This study reported no
significant differences inETECdiarrhoea, severe ETECdiarrhoea,
or all-cause diarrhoea (one trial, 134 participants, Analysis 4.1;
Analysis 4.2; Analysis 4.3).
Safety
This outcome was not reported.
Immunological response
This outcome was not reported.
Analysis 5: Live attenuated ETEC vaccine (PTL-003)
Clinical efficacy
McKenzie 2008 evaluated PTL-003, a live attenuated ETEC-spe-
cific vaccine, in a small artificial challenge study in North Amer-
ican volunteers. The authors reported no statistically significant
reduction in ETEC diarrhoea (one trial, 33 participants, Analysis
5.1; Analysis 5.2).
Safety
McKenzie 2008 reported safety data. No statistically significant
differences in adverse events were observed between vaccine and
control groups (one trial, 33 participants, Analysis 5.3).
Immunological response
McKenzie 2008 reported the proportion of participants with a >
two-fold increase in CF-specific antibody responses against CS1
and CS3 and found significantly higher IgA titres in vaccinees
compared to controls (see Table 6). There were no significant
differences in toxin-specific antibody responses (Analysis 5.4).
Transcutaneous vaccines versus placebo
Analysis 6: Transcutaneous LT patch
Clinical efficacy
An LT-ETEC vaccine delivered via a transcutaneous patch was
evaluated in one natural challenge study in American adults in-
tending to travel to Mexico and Guatemala (Frech 2008) and
in one artificial challenge study in North American volunteers
(McKenzie 2007). No statistically significant differences were re-
ported for ETEC diarrhoea, severe ETEC diarrhoea, or all-cause
diarrhoea (two trials, 217 participants, Analysis 6.1; Analysis 6.2;
Analysis 6.3).
Safety
A total of 260 participants from two studies were evaluated for
safety data, particularly regarding reactogenicity at the application
site and other systemic adverse events (McKenzie 2007; Frech
2008). A significantly higher number of local immune reactions in
the form of rash (P < 0.00001), pruritus (P < 0.00001), and skin
discolouration (P = 0.0003) were observed in people that received
the vaccine compared to placebo recipients (Analysis 6.4). For
other events, there were no significant differences (Analysis 6.4).
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Immunological Response
Frech 2008 and McKenzie 2007 reported a > four-fold increase in
toxin-specific IgA antibody responses in 82% and 93% of people
vaccinated, respectively (RR 43.0, 95% CI 12.33 to 149.97, P <
0.00001; two trials, 217 participants, Analysis 6.5).
Passive immunization versus placebo
Analysis 7: Hyperimmune anti-ETEC CFA
Clinical efficacy
Two artificial challenge studies reported passive immunization us-
ing bovine hyperimmune anti-ETEC CFA in North American
volunteers (Freedman 1998; Tacket 1999). The authors did not
find any significant protective efficacy against all-cause diarrhoea
(two trials, 45 participants, Analysis 7.1).
Safety
A total of 45 participants from the studies by Freedman 1998
and Tacket 1999 were evaluated for safety data. A significantly
higher number of events occurred in people that were vaccinated
compared to those that received a placebo regarding the events of
anorexia (P = 0.01) and abdominal pain (P = 0.003) (Analysis 7.2).
For other events, there were no significant differences between
people that were vaccinated and those that received a placebo
(Analysis 7.2).
Immunological Response
No immunological data were reported.
D I S C U S S I O N
Summary of main results
In this review, we included 24 trials and 53,247 participants. Four
studies assessed the protective efficacy of oral cholera vaccines
when used to also prevent diarrhoea due to ETEC and eight trials
assessed the protective efficacy of ETEC-specific vaccines.
Cholera vaccines
A single RCT evaluated the currently available oral cholera killed
whole cell vaccine (Dukoral®) for protection against ’travellers’
diarrhoea’ in people arriving in Mexico from the USA. There were
no statistically significant effects on ETEC diarrhoea or all-cause
diarrhoea (one trial (Scerpella 1995), 502 participants, low quality
evidence).
Two earlier trials, one in an endemic population in Bangladesh
(Clemens 1988) and one in travellers from Finland to Morocco
(Peltola 1991), evaluated a precursor of this vaccine containing
purified cholera toxin B subunit, rather than the recombinant
subunit inDukoral®. Short termprotective efficacy against ETEC
diarrhoea was demonstrated lasting for around three months (two
trials, 50,227 participants). This vaccine is no longer available.
ETEC vaccines
An ETEC-specific killed whole cell vaccine, also containing the
recombinant cholera toxin B-subunit, was evaluated in people
travelling from the USA to Mexico or Guatemala (Sack 2007),
and from Austria to Latin America, Africa, or Asia (Wiedermann
2000). There were no statistically significant differences in ETEC-
specific diarrhoea or all-cause diarrhoea (two trials, 799 partic-
ipants) and the vaccine was associated with increased vomiting
(nine trials, 1528 participants) (Cohen 2000 (Study 1); Cohen
2000 (Study 2); Qadri 2003; Qadri 2006a; Sack 2007; Savarino
1998; Savarino 1999 (Study 1); Savarino 1999 (Study 2); Savarino
2002). The other ETEC-specific vaccines in development have
not yet demonstrated clinically important benefits.
Overall completeness and applicability of
evidence
The use of the oral choleraWC-rCTB vaccine for preventing ’trav-
ellers’ diarrhoea’ has been based on the findings of two trials that
demonstrated some short termprotection against ETECdiarrhoea
(Clemens 1988; Peltola 1991). The vaccine used in both of these
trials contained 1 mg of purified cholera B-subunit, rather than
the recombinant B-subunit in the current vaccine. It should be
noted that the cholera B-subunit is the only element of this vaccine
which could be expected to induce immunity to ETEC. These
two vaccines were directly compared in a single trial of 41 Swedish
volunteers (Jertborn 1992), which reported comparable cholera-
specific antibody responses but did not evaluate either clinical or
immunological protection against ETEC. The finding of limited
protective benefit with the cholera WC-rCTB vaccine (Scerpella
1995) is supported by two further trials evaluating the ETECWC-
rCTB vaccine which contains the same recombinant cholera B-
subunit, and also found no evidence of clinical protection in trav-
ellers (Wiedermann 2000; Sack 2007). These three trials raise con-
cerns that the earlier findings may not be applied to the current
vaccine.
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In addition, the large study from Bangladesh (Clemens 1988),
which contributed over 90% of participants included in this re-
view, aimed primarily to assess the protective efficacy against
cholera not ETEC. The assessment of protective efficacy against
ETEC therefore represented a post-hoc analysis. This trial was
conducted among an endemic population who were likely to have
acquired some natural immunity against ETEC. The results of
this study may therefore be poorly applicable to travellers.
The ETEC-specific vaccines are now primarily being designed for
use in developing country settings for prevention of ETEC diar-
rhoea in infants and young children, although protection of trav-
ellers remains important (Holmgren 2012). Promising CFs and
toxin-specific immune responses to the ETECWC-rCTB vaccine
have been observed. However, following failure to demonstrate
clinical protective efficacy and safety concerns, further pre-clini-
cal development of this vaccine is underway (Tobias 2012). Sev-
eral additional vaccine candidates not included in this review are
currently at early stages of development. In Sweden, an oral inac-
tivated tetravalent ETEC vaccine alone or together with double
mutant heat labile toxin (dmLT) adjuvant is undergoing testing in
Phase I/II studies. In the USA an oral live attenuated three strain
recombinant ETEC vaccine, ACE527, is undergoing testing with
plans formovingfield sites in developing countries (Darsley 2012).
Quality of the evidence
The quality of the evidence for the oral cholera vaccine (Dukoral®)
was assessed using the GRADE approach. Clinically important
benefits of this vaccine have not yet been demonstrated and the
quality of this evidence was downgraded to ’low’. This means that
use of this vaccine may have little or no difference in preventing
ETEC diarrhoea but further research may change this result. The
quality was downgraded due to concerns about the applicability
of the evidence. Most cases of ETEC diarrhoea occurred prior to
completion of the vaccine schedule (indirectness) and the sample
size was small (imprecision) (Summary of findings for the main
comparison).
Agreements and disagreements with other
studies or reviews
A previous review of vaccination to prevent ETEC diarrhoea con-
cluded that the protective effect of Dukoral® was up to 43% and
that it should be recommended for travellers (Jelinek 2008). How-
ever, this conclusion was based predominantly on positive find-
ings from the older trials assessing prototypes of the Dukoral®
vaccine, on subgroup analyses which may or may not have been
pre-planned, or on the findings of non-randomized retrospective
studies.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is currently insufficient evidence from RCTs to support the
use of the oral cholera vaccine (Dukoral®) for protecting travellers
against ETEC diarrhoea.
Implications for research
Further research is needed to develop safe, immunogenic, and
effective vaccines to provide both short and long term protection
against ETEC diarrhoea.
More studies are needed to evaluate the efficacy of new and can-
didate vaccines for safety and immunogenicity in naive adult trav-
ellers, and exposed and primed populations in a developing coun-
try setting where children and infants will be the major targets for
future vaccination. ETEC vaccine development needs to include
plans for overcoming barriers to oral vaccination in children. Also,
strategies are needed to deliver the vaccines using the existing na-
tional immunization system of these countries, including the EPI,
the cold chain facilities, and other national health facilities. In
addition, the use of different modes of delivery of vaccines (in-
cluding use of mucosal adjuvants) needs to be studied to improve
immunogenicity and efficacy of ETEC vaccines.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Clemens 1988
Methods Study type: Randomized, natural challenge, efficacy study in an endemic population
Trial dates and duration: From January 1985 to May 1986
Surveillance: Surveillance for diarrhoea was done at treatment centres serving the study
participants at Matlab for 365 post-vaccination days
Participants Number of participants: 49,612
Inclusion criteria: People aged between 2 to 15 years of age and female subjects > 15
years of age residing in Matlab
Exclusion criteria: Persons who were absent or refused to participate, pregnant, or suf-
fering from any other illness
Interventions Vaccine: Cholera toxin B subunit plus killed cholera whole cells (BS-WC)
Control: Killed cholera whole cells (WC)
Additional details: In this study participants received 3 doses of vaccine at 6 weeks
apart, of BS-WC vaccine, WC vaccine only, or an E. coli K12 strain placebo. However,
protective efficacy was calculated based on WC vaccine as control and BS-WC as study
intervention group, because the killed cholera whole cells, which were identical for the
BS-WC and WC vaccines, were not anticipated to have any protective effects against
LT-ETEC
Outcomes Included in review:
• Episodes of diarrhoea
• LT-ETEC diarrhoea
Notes Location: Matlab, Bangladesh
Setting: Three different treatment centres at Matlab, a rural setting of Bangladesh
Source of funding: US agency for International Development, the Government of Japan,
the Swedish agency for Research Cooperation with Developing Countries and theWorld
Health Organization (WHO)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”After computerisation of the census, we
assigned every person in the eligible age-
gender categories to letters A, B or C,
using simple randomisation“ (from addi-
tional paper describing this study)
Allocation concealment (selection bias) Low risk ”The agents were identified only by the let-
ters A, B and C“ (from an additional paper
describing this study)
Allocation concealed.
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Clemens 1988 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ”During the conduct of the study, the
identities of these letter...were unknown
to all persons connected with the trial in
Bangladesh“
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk ”During the conduct of the study, the
identities of these letter...were unknown
to all persons connected with the trial in
Bangladesh“
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Losses to follow-up were not clearly de-
scribed.
Selective reporting (reporting bias) High risk This was a three arm study. It was unclear
why the group given the cholera WC vac-
cine was selected as the control arm rather
than the group given a placebo
Other bias Low risk None identified.
Cohen 2000 (Study 1)
Methods Study type: Randomized safety and immunogenicity study in volunteers
Trial dates and duration: Between May 22 and July 10 1995
Participants Number of participants: 65
Inclusion criteria: Healthy men and women and were recruited among the School of
Military Medicine cadets or the Medical Corps Headquarters staff
Exclusion criteria: Not described.
Interventions Vaccine: Contained 1.0 mg of rCTB plus a final count of 1011 formalin-inactivated
bacteria. Each vaccine dose included the following inactivated ETEC strains: SBL 101
(O78, CFA/I, LT2/ST1), SBL 106 (O6, CS1, LT2/ST2), SBL 107 (OR, CS2, CS3,
LT2/ST2), SBL 104 (O25, CS41CS6, LT2/ST2) and SBL 105 (O167, CS51CS6, LT2/
ST2)
Placebo: Heat-killed E. coli K12 with an optical density (OD) equivalent to that of the
ETEC vaccine, was administered in the same buffered solution as the vaccine
Additional details: Each dose of lot E003 was given in 150 mL of water with a raspberry-
flavoured bicarbonate-citric acid buffer containing 4 g of sodium bicarbonate per dose
(Recip AB, Stockholm, Sweden)
Outcomes Included in review:
• Adverse events
• CF-specific antibody (CFA) responses
• Toxin-specific antibody (TSA) responses
Not included in the review:
• All cases of ETEC diarrhoea
• All cases of ETEC illness
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Cohen 2000 (Study 1) (Continued)
Notes Location: Israel
Setting: Israel Defence Force (IDF), Medical Corps, ArmyHealth Branch ResearchUnit,
and the IDF, Medical Corps, School of Military Medicine
Source of funding: US Army Medical Research & Material Command (DAMD 17-93-
V-3001)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ”Group randomization was used so that
each group was assigned two letters, and
each volunteer was openly allotted to one
of the four resulting letter groups“
It is unclear if this method was truly ran-
dom.
Allocation concealment (selection bias) Low risk ”Each volunteer was openly allotted to one
of the four resulting letter groups. The as-
sociation between a letter group and a vac-
cine/placebo group was determined by a
third party and was kept locked from both
volunteers and investigators for the dura-
tion of the study“
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ”The placebo preparation, containing a
suspension of heat-killed E. coli K12 with
an optical density (OD) equivalent to that
of the ETEC vaccine, was administered in
the same buffered solution as the vaccine“
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk See above.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses to follow-up were low: 3 out of 33
(9%) in the vaccine group and 2 out of 31
(6%) in controls either dropped out of the
study or were not given the second dose
Selective reporting (reporting bias) Low risk None identified.
Other bias Low risk None identified.
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Cohen 2000 (Study 2)
Methods Study type: Randomized, safety and immunogenicity study in volunteers
Trial dates and duration: Between April 1 and June 18 1997
Participants Number of participants: 90
Inclusion criteria: Healthy men and women and were recruited among the School of
Military Medicine cadets or the Medical Corps Headquarters staff
Exclusion criteria: Not mentioned
Interventions Vaccine: Contained 1.0 mg of rCTB plus a final count of 1011 formalin-inactivated
bacteria. Each vaccine dose included the following inactivated ETEC strains: SBL 101
(O78, CFA/I, LT2/ST1), SBL 106 (O6, CS1, LT2/ST2), SBL 107 (OR, CS2, CS3,
LT2/ST2), SBL 104 (O25, CS41CS6, LT2/ST2) and SBL 105 (O167, CS51CS6, LT2/
ST2)
Placebo: Heat-killed E. coli K12 with an optical density (OD) equivalent to that of the
ETEC vaccine, was administered in the same buffered solution as the vaccine
Additional details: Each dose of lot E005 was given in 150 mL of water with a raspberry-
flavoured bicarbonate-citric acid buffer containing 4 g of sodium bicarbonate per dose
(Recip AB, Stockholm, Sweden)
Outcomes Included in review:
• Adverse events
• Colonization factor-specific antibody (CFA) responses
• TSA responses
Not included in the review:
• All cases of ETEC diarrhoea
• All cases of ETEC illness·
Notes Location: Israel
Setting: IDF, Medical Corps, Army Health Branch Research Unit, and the IDF, Medical
Corps, School of Military Medicine
Source of funding: US Army Medical Research & Material Command (DAMD 17-93-
V-3001)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”A blocked randomization scheme was
constructed off-site“.
Allocation concealment (selection bias) Low risk ”Subjects were assigned a unique partici-
pant identification number (101 to 190) at
the time of the first dose and received the
correspondingly labelled study agent“
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ”The placebo preparation, containing a
suspension of heat-killed E. coli K-12 with
an optical density (OD) equivalent to that
of the ETEC vaccine, was administered in
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Cohen 2000 (Study 2) (Continued)
the same buffered solution as the vaccine“
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk ”The investigation team remained blinded
until all safety and immunogenicity data
were generated, computerized, cleaned,
and locked“
Incomplete outcome data (attrition bias)
All outcomes
High risk Losses to follow-up were moderate: 8 out
of 45 (18%) in the vaccine group and 4 out
of 45 (9%) in controls either dropped out
of the study or were not given the second
dose
Selective reporting (reporting bias) Low risk None identified.
Other bias Low risk None identified.
Frech 2008
Methods Study type: Randomized, natural challenge, efficacy study in travellers
Trial dates and duration: May 2006 to February 2007
Surveillance: Surveillance was conducted on US travellers who visited to Mexico and
Guatemala
Participants Number of participants: 201
Inclusion criteria: Healthy adults aged 18 to 64 years, who planned to travel to Cuer-
navaca, Guadalajara, SanMiguel, or Cancun (Mexico), or Antigua (Guatemala) and who
had access to one of the 14 US regional vaccination centres
Exclusion criteria: History of travellers’ diarrhoea and travelled to an endemic country
in the previous 12 months, history of taking cholera, LT or ETEC vaccine, significant
illness, immunosuppression or if female, pregnant, nursing, or unwilling to use effective
form of any contraceptives
Interventions Vaccine: LT patch; 37.5 µg of ETEC LT
Placebo: All the excipients of LT patch without LT
Additional details: Vaccinations with either an LT patch or placebo patch were given
to alternate upper arms a minimum of 3 weeks (first vaccination) and 1 week (second
vaccination) before departure
Outcomes Included in review:
• ETEC diarrhoea
• Severe ETEC diarrhoea
• All-cause diarrhoea
• Any ETEC illness
• Severe ETEC illness
• Adverse events
• Immunological response
27Vaccines for preventing enterotoxigenic Escherichia coli (ETEC) diarrhoea (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Frech 2008 (Continued)
Notes Location: Mexico and Guatemala
Setting: University of Texas Health Science Center at Houston (Houston, TX, USA),
Universidad Del Valle De Guatemala (Guatemala City, Guatemala), Inovamed Hospital
(Cuernavaca, Mexico) and ViroMed Laboratory, Minnetonka, MN, USA
Source of funding: IOMAI corporation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”The study used a web-based, audit-trail
enabled, centralised randomisation code
and allocation system“
Allocation concealment (selection bias) Low risk ”Vaccination sites accessed a web page, en-
tered participants into the system, and re-
ceived unique patch numbers for every
study participant“
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ”Dose information was masked at alloca-
tion, as well as on primary and secondary
product packaging. Participants and site
staff, including those assessing study out-
comes, remained masked until database
lock“
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk See above.
Incomplete outcome data (attrition bias)
All outcomes
High risk Losses to follow-up were high: 8 out 67
(12%) in the vaccine group and 23 out of
134 (17%) in the placebo group due to fail-
ure to: receive second dose of vaccine, pro-
vide diary cards, or attend in-country visit
Selective reporting (reporting bias) Low risk None identified.
Other bias Low risk None identified.
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Freedman 1998
Methods Study type: Randomized, artifical challenge, efficacy study in volunteers
Trial dates and duration: Not given
Surveillance: Daily medical rounds were conducted to monitor symptoms during the 7
days of study period. Daily stool samples were taken for bacteriologic examination
Artificial challenge: On day 4
Participants Number of participants: 25
Inclusion criteria: Not described
Exclusion criteria: Not described
Interventions Vaccine: Each lyophilized dose containing hyperimmune anti-E. coli bovine milk IgG
dissolved in 150 mL of bicarbonate solution
Placebo: A single dose of a lactose-free infant formula
Additional details: Three doses/day for 7 days, vaccine, or placebo were administered 15
minutes after meals
Artificial challenge: 109 cfu of H10407 (O78:H11), a CFA/I-bearing ETEC strain sus-
pended in 1 ounce (30 mL) of water containing sodium bicarbonate
Outcomes Included in review:
• All-cause diarrhoea
• CF-specific immune responses
• Toxin-specific antibody responses
• Adverse events
Notes Location: Baltimore, MD, USA
Setting: Center for Vaccine Development (University of Maryland School of Medicine)
Source of funding: ImmuCell
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”The randomization list was generated and
secured by ImmuCell’s Quality Assurance
Supervisor“
Allocation concealment (selection bias) Low risk ”by assigning subject identification num-
bers to identically packaged foil pouches
containing measured doses of each test ar-
ticle“
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ”All investigators and volunteers were
blinded to these treatment group assign-
ments throughout the study and during as-
sessment of outcome“
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk See above.
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Freedman 1998 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No drop-outs occurred.
Selective reporting (reporting bias) Low risk None identified.
Other bias Low risk None identified.
Hall 2001 (Study 1)
Methods Study type: Randomized, safety and immunogenicity study in volunteers
Trial dates and duration: Not mentioned in the article
Surveillance: Subjects were randomly assigned to receive two doses of vaccine or placebo
2 weeks apart
Participants Number of participants: 76
Inclusion criteria: Adults aged between 21 and 45 years from Benha, Qalyubia Gover-
norate, Egypt
Exclusion criteria: Not mentioned
Interventions Vaccine: Each 4 mL vaccine dose (lot E003) contained 1 mg of rCTB plus a mixture of
2 x 1010 bacteria each of five strains individually expressing CFA/I, CS1, CS2 plus CS3,
CS4, and CS5
Placebo: Each 4-mL placebo dose contained 1011 heat-killed E. coli K12 cells
Additional details: Each dose was added to 150 mL of water containing 4 g of sodium
bicarbonate plus 1.45 g of citric acid (Recip AB, Stockholm, Sweden) for adult admin-
istration
Outcomes Included in review:
• CFA responses
• TSA responses
Not included in the review:
• Adverse events
• All cases of ETEC diarrhoea
• All cases of ETEC illness·
Notes Location: Egypt
Setting: Benha, Qalyubia Governorate, Egypt
Source of funding: Naval Medical Research and Development Command (B69000101.
PIX3270), Intragency Agreement Y1-HD-0026-01, the National Institute of Child
Health and Human Development and WHO Global Programme for Vaccines and Im-
munization Research and Development
Risk of bias
Bias Authors’ judgement Support for judgement
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Hall 2001 (Study 1) (Continued)
Random sequence generation (selection
bias)
Unclear risk ”After enrollment, subjects were random-
ized to receive vaccine or placebo in a dou-
ble-blind fashion within blocks of 4 se-
quentially randomized subjects“ (Savarino
1998).
It is unclear if this was truly random.
Allocation concealment (selection bias) Low risk ”At the time of initial dosing, each subject
was assigned a sequential number corre-
sponding to sequentially numbered single-
dose vials of study agent“ (Savarino 1998).
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as ”double blind, placebo con-
trolled“, and vaccines labelled only with
study code
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk ”The code was broken after all clinical and
laboratory evaluations were completed“
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses to follow-up were low: 2/49 (4%)
in the vaccine group and 2/48 (4%) in the
placebo group
Selective reporting (reporting bias) Low risk None identified.
Other bias Low risk None identified.
Hall 2001 (Study 2)
Methods Study type: Randomized, safety and immunogenicity study in volunteers
Trial dates and duration: Not mentioned in the article
Surveillance: Subjects were randomly assigned to receive two doses of vaccine or placebo
2 weeks apart
Participants Number of participants: 107
Inclusion criteria: School children aged between 6 to 12 years old from Benha, Qalyubia
Governorate, Egypt
Exclusion criteria: Not mentioned
Interventions Vaccine: Each 4 mL vaccine dose (lot E003) contained 1 mg of rCTB plus a mixture of
2 x 1010 bacteria each of five strains individually expressing CFA/I, CS1, CS2 plus CS3,
CS4, and CS5
Placebo: Each 4 mL placebo dose contained 1011 heat-killed E. coli K12 cells.
Additional details: Each dose was added to 75 mL of water containing 4 g of sodium
bicarbonate plus 1.45 g of citric acid (Recip AB, Stockholm, Sweden) for school children
administration
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Hall 2001 (Study 2) (Continued)
Outcomes Included in review:
• CFA responses
• TSA responses
Not included in the review:
• Adverse events
• All cases of ETEC diarrhoea
• All cases of ETEC illness·
Notes Location: Egypt
Setting: Benha, Qalyubia Governorate, Egypt
Source of funding: Naval Medical Research and Development Command (B69000101.
PIX3270), Intragency Agreement Y1-HD-0026-01, the National Institute of Child
Health and Human Development and WHO Global Programme for Vaccines and Im-
munization Research and Development
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ”After enrollment, subjects were random-
ized to receive vaccine or placebo in a dou-
ble-blind fashion within blocks of 4 se-
quentially randomized subjects“ (Savarino
1998).
It is unclear if this was truly random.
Allocation concealment (selection bias) Low risk ”At the time of initial dosing, each subject
was assigned a sequential number corre-
sponding to sequentially numbered single-
dose vials of study agent“ (Savarino 1998).
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as ”double blind, placebo con-
trolled“, and vaccines labelled only with
study code
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk ”The code was broken after all clinical and
laboratory evaluations were completed“
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up occurred.
Selective reporting (reporting bias) Low risk None identified.
Other bias Low risk None identified.
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Hall 2001 (Study 3)
Methods Study type: Randomized, safety and immunogenicity study in volunteers
Trial dates and duration: Not mentioned in the article
Surveillance: Subjects were randomly assigned to receive two doses of vaccine or placebo
2 weeks apart
Participants Number of participants: 106
Inclusion criteria: Preschool children aged between 2 to 5 years old fromBenha,Qalyubia
Governorate, Egypt
Exclusion criteria: Not mentioned
Interventions Vaccine: Each 4 mL vaccine dose (lot E003) contained 1 mg of rCTB plus a mixture of
2 x 1010 bacteria each of five strains individually expressing CFA/I, CS1, CS2 plus CS3,
CS4, and CS5
Placebo: Each 4 mL placebo dose contained 1011 heat-killed E. coli K12 cells
Additional details: Each dose was added to 37.5 mL of water containing 4 g of sodium
bicarbonate plus 1.45 g of citric acid (Recip AB, Stockholm, Sweden) for adult admin-
istration
Outcomes Included in review:
• CFA responses
• TSA responses
Not included in the review:
• Adverse events
• All cases of ETEC diarrhoea
• All cases of ETEC illness·
Notes Location: Egypt
Setting: Benha, Qalyubia Governorate, Egypt
Source of funding: Naval Medical Research and Development Command (B69000101.
PIX3270), Intragency Agreement Y1-HD-0026-01, the National Institute of Child
Health and Human Development and WHO Global Programme for Vaccines and Im-
munization Research and Development
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “After enrollment, subjects were random-
ized to receive vaccine or placebo in a dou-
ble-blind fashion within blocks of 4 se-
quentially randomized subjects” (Savarino
1998).
It is unclear if this was truly random.
Allocation concealment (selection bias) Low risk ’At the time of initial dosing, each subject
was assigned a sequential number corre-
sponding to sequentially numbered single-
dose vials of study agent“ (Savarino 1998).
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Hall 2001 (Study 3) (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as ”double blind, placebo con-
trolled“, and vaccines labelled only with
study code
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk ”The code was broken after all clinical and
laboratory evaluations were completed“
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only one participant was lost to follow-up
(from the placebo group)
Selective reporting (reporting bias) Low risk None identified.
Other bias Low risk None identified.
Jertborn 1998
Methods Study type: Randomized, safety study in volunteers
Study 1: Single blinded, placebo controlled, randomized study
Study 2: Non-placebo controlled study (data excluded)
Study 3: Non-placebo controlled study (data excluded)
Trial dates and duration: Not mentioned in the article
Surveillance: Study 1: 5 consecutive post vaccination days
Participants Number of participants: 20 (vaccine) plus 20 (placebo)
Inclusion criteria: Adult Swedish volunteers, aged between 20 to 50 years were recruited,
with no history of travel to an endemic country for the past 6 months
Exclusion criteria: Not mentioned
Interventions Vaccine: One single dose of vaccine contained 1.0 mg of rCTB and 1011 formalin-
inactivated enterotoxigenic E. coli bacteria of each of the following strains: O78:H12-
CFA/I ST+, O25:H42- CS4+CS6, O167:H5-CS5+CS6/ST+, O6:H16-CS2+CS3, and
O139:H28-CS1
Placebo:One single dose of placebo consisted of 150mLof a sodiumbicarbonate solution
(Samarin; Cederroths Nordic AB, Upplands Vasby, Sweden)
The volunteers were instructed not to eat or drink (except water) for 1 hour before and
after intake of the vaccine or placebo preparation
Outcomes Included in review:
• Adverse events
Notes Location: Goteborg, Sweden
Setting: University of Goteborg, Sweden
Source of funding: Swedish Research Council (16X-09084 and 16X-3382), the Swedish
Agency for Research Cooperation with Developing Countries, the WHO and the Med-
ical Faculty, Goteborg University
Risk of bias
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Jertborn 1998 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as ”randomized“. No further de-
tails.
Allocation concealment (selection bias) Unclear risk None described.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Described as ”single blind“ but no further
details.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Described as ”single blind“ but no further
details.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses to follow-up were low: 1 out of 20
in placebo group was excluded due to viral
infection
Selective reporting (reporting bias) Low risk None identified.
Other bias Low risk None identified.
Jertborn 2001
Methods Study type: Randomized, immunogenicity study in volunteers
Study 1: Open study without any control group (excluded from the review))
Study 2: Double blinded, placebo controlled, randomized study
Trial dates and duration: Not mentioned in the article
Surveillance: Not described
Participants Number of participants:
Study 1: 36 (excluded from the review)
Study 2: 31
Inclusion criteria: Adult Swedish volunteers, aged between 18 to 46 years were recruited,
no history of travelling to ETEC endemic areas for 6 months prior to the study
Exclusion criteria: Not mentioned
Interventions Vaccine:
Study 1: One 4 mL dose of vaccine (Lot 003) contained 1.0 mg of rCTB and 1011
formalin-inactivated E. coli bacteria of each of the following strains: SBL101 (O78:H12;
CFA/I ST1), SBL104 (O25:H42; CS4), SBL105 (O167:H5; CS5 ST1), SBL 106 (O6:
H16; CS1), and SBL 107 (OR:H6; CS21 CS3) (Data not included in the review)
Study 2: Different lot (Lot 005) of vaccine with same formulation except the half the
amount of CFA/I and three times more CS2 than lot 003 was used in this study
Placebo: The 4 mL placebo dose consisted of 1 ×1011 heat-killed E. coli K12 bacteria
Additional details: Each dose of a study agent was administered in 150 mL of a sodium
bicarbonate solution (Samarin; Cederroths Nordic AB, Upplands Vasby, Sweden). The
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Jertborn 2001 (Continued)
volunteers were instructed not to eat or drink (except water) for 1 hour before and after
intake of the vaccine or placebo preparation
Outcomes Included in review:
• Immunological response
Notes Location: Goteborg, Sweden
Setting: University of Goteborg, Sweden
Source of funding: Swedish Research Council (16X-09084), the Swedish Agency for
Research Cooperation with Developing Countries, the WHO and the Medical Faculty,
Goteborg University
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as ‘randomized’, no further de-
tails given.
Allocation concealment (selection bias) Unclear risk None described.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Described as ‘double blind, Placebo con-
trolled“ study, no further details
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk As above.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No drop-outs occurred.
Selective reporting (reporting bias) Low risk None identified.
Other bias Low risk None identified.
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Leyten 2005
Methods Study type: Randomized, natural challenge, efficacy study in travellers
Trial dates and duration: May 1995 to February 1996
Surveillance: All participants kept a diary of their defecation pattern during their stay
abroad. On return, they filled out a questionnaire concerning defecation pattern, use of
medication and
information regarding travel, accommodation, and dietary hygiene. Each participant
submitted a stool specimen. Subjects who had experienced an episode of diarrhoea during
travel collected a sample during the first diarrhoeal episode, prior to having taken any
medication. The remaining travellers collected and submitted a sample within 3 days
after returning home
Participants Number of participants: 145
Inclusion criteria: Dutch volunteers, travellers from the travellers clinics of the Leiden
University Medical Centre (LUMC), the Netherlands, the Municipal Health Centre at
Leiden and the Harbour Hospital at Rotterdam. All adults who were intending to travel
to Indonesia, Thailand, the Indian subcontinent or West Africa (Gambia or Senegal) for
a period of 1 to 4 weeks were invited to take part in the trial
Exclusion criteria: People suffering from acute or chronic inflammatory disease of the
intestinal tract, prior recipients of WC-BS cholera vaccine or CVD 103-HgR vaccine,
subjects receiving immunosuppressive drugs, persons known to be immunodeficient,
subjects participating in other clinical trials women who were either pregnant or breast-
feeding
Interventions Vaccine: CVD 103-HgR, Single dose of 5 x 108 cfu of lyophilized CVD 103-HgR live
oral cholera vaccine
Placebo: 5 x 108 heat-killed E. coli K12
Additional details: Vaccine has been administered orally. Both vaccine and placebo are
identical in appearance
Outcomes Included in review:
• ETEC diarrhoea
• Severe ETEC diarrhoea
• All-cause diarrhoea
• Any ETEC illness
• Severe ETEC illness
Notes Location: The Netherlands
Setting: Leiden University Medical Center (LUMC)
Source of funding: Berna Biotech AG, Bern, Switzerland
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “For randomisation a computer-generated
randomisation list, was used”
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Leyten 2005 (Continued)
Allocation concealment (selection bias) Low risk “Sachets and suspensions of vaccine and
placebo that were identical in appearance,
were labelled by a coded number from 1 to
200”
Allocation was concealed through random-
ization to identical coded vials
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk See above.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The key to the coded sachets was stored
at the hospital pharmacy in a sealed enve-
lope. The envelope was only to be opened
by the investigator in case of an emergency
that required knowledge of the identity of
the trial medication in order to manage the
participant’s condition. At the end of the
trial the coded envelope was returned to the
Berna Biotech AG and checked to ensure
that the seal had remained unbroken“
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses to follow-up were low: in vaccine
group 4/73 (5%) and in placebo group 7/
72 (10 %)
Selective reporting (reporting bias) Low risk None identified.
Other bias Low risk None identified.
McKenzie 2007
Methods Study type: Randomized, artificial challenge, efficacy study in volunteers
Trial dates and duration: September 15 2004 to June 30 2005
Surveillance: Post vaccination follow-up on day 0, 7, 21, 28, 42, 49, and 77; Artificial
challenge: on day 55; Post challenge follow-up for 5 days
Participants Number of participants: 59
Inclusion criteria: Healthy adults, between 18 to 45 years of age
Exclusion criteria: Clinically significant medical conditions, history of traveller’s diar-
rhoea in the last 3 years and LT IgG titer > 2000 EU by ELISA
Interventions Vaccine: 150 µL of saline containing 50 µg of LT
Placebo: 150 µL of saline containing no LT
Additional details: All participants were randomized to receive transcutaneous applica-
tion of 3 doses saline containing LT or saline only, at an interval of 21 days
Artificial challenge: 120 mL of sodium bicarbonate buffer containing 6 × 108 CFU of
the challenge virulent strain of E. coli E24377A
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McKenzie 2007 (Continued)
Outcomes Included in review:
• ETEC diarrhoea
• Severe ETEC diarrhoea
• All-cause diarrhoea
• Any ETEC illness
• Severe ETEC illness
• Adverse events
• Immunological response
Notes Location: USA
Setting: Vaccine Testing Unit, the Center for Immunization Research (CIR), JohnsHop-
kins Bloomberg School of Public Health, Baltimore, MD, USA; IOMAI Corporation,
Gaithersburg, MD, USA; Amarex Clinical Research, Germantown, MD, USA
Source of funding: IOMAI Corporation, Gaithersburg, MD, USA
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”The randomization list was generated by
the statistician“.
Allocation concealment (selection bias) Unclear risk None described.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Described as ”double blind“ but no details
given of how this was done
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Described as ”double blind“ but no details
given of how this was done
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2 out of 30 (7%) subjects from vaccine
group and 4 out 29 (14%) of subjects from
placebo group subsequentlywithdrew from
the study before the inpatient challenge
phase.However, once entered into the chal-
lenge phase there were no further drop-outs
Selective reporting (reporting bias) Low risk None identified.
Other bias Low risk None identified.
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McKenzie 2008
Methods Study type: Randomized, artificial challenge, efficacy study in volunteers
Trial dates and duration: Not mentioned in the article
Surveillance: Post vaccination follow-up for 20 days
Artificial challenge: On day 27; post challenge follow-up for 5 days (passive using diary
cards)
Participants Number of participants: 39
Inclusion criteria: Healthy adults, 18 to 50 years of age
Exclusion criteria: Not mentioned in the article
Interventions Vaccine: PTL-003 ( PTL-003 was derived from the spontaneously toxin-negative, O139:
H28 ETEC strain E1392/75-2A containing 2 × 109 cfu/mL live attenuated bacteria in
200 mL of CeraVacxT M buffer)
Placebo: CereVacx buffer (CeraVacx, Cera Products Inc., Jessup, MD: rice solids, 7.0 g;
sodium bicarbonate, 2 g; trisodium citrate, 0.5 g in 200 mL of water)
Additional details: All participants were randomized to receive 2 doses, at an interval of
10 days
Artificial challenge: 30 mL of sodium bicarbonate buffer containing 3 × 109 CFU of the
challenge virulent strain of E. coli E24377
Outcomes Included in review:
• ETEC diarrhoea
• Severe ETEC diarrhoea
• All-cause diarrhoea
• Any ETEC illness
• Severe ETEC illness
• Adverse events
• Immunological response
Notes Location: USA
Setting: Vaccine Testing Unit, the Center for Immunization Research (CIR), Johns
Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
Source of funding: Acambis Research Ltd., Cambridge, UK and by Johns Hopkins
University School of Medicine General Clinical Research Center grant number M01-
RR00052 from the National Center for Research Resources, NIH
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as ”randomized“, no further de-
tails given.
Allocation concealment (selection bias) Unclear risk None described.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Described as ”double blind“, no further de-
tails given.
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McKenzie 2008 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Described as ”double blind“, no further de-
tails given.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses to follow-up were low (three partic-
ipants in each group withdrew before the
challenge phase), but as the trial was very
small this represented 15% of all partici-
pants. However once they entered the chal-
lenge phase, there was no further drop-outs
Selective reporting (reporting bias) Low risk None identified.
Other bias Low risk None identified.
Peltola 1991
Methods Study type: Randomized, natural challenge, efficacy study in travellers
Trial dates and duration: October 24 1989 to November 21 1989
Surveillance: Any diarrhoea during the trip period and immediately after returning back
was recorded and stool samples were collected
Participants Number of participants: 615
Inclusion criteria: Travellers from Finland to Morocco
Exclusion criteria: Travellers aged less than 15 years and history of taking antimicrobials
during the previous 7 days of vaccination days
Interventions Vaccine: 1 x 1011 heat-killed whole cells of V. cholerae with 1 mg of the B-subunit of
cholera toxin
Placebo: E. coli K12
Additional details: Two doses of vaccine or placebo identical in appearance, 3 and 1 week
before the departure were administered
Outcomes Included in review:
• All cases of ETEC diarrhoea
• Severe cases of ETEC diarrhoea
• All-cause diarrhoea
• Adverse events
Notes Location: Finland and Morocco
Setting: Enteric Laboratory, Moroccan Health Authority, Agadir, Morocco; Laboratory
of Enteric Pathogen, The National Public Health Institute, Helsinki, Finland
Source of funding: National Public Health Authority, Finland, Fintours Company, Sun
Tours Company, Moroccan Health Authority, University of Gothenburg, Pohjola Com-
pany, and Tapiola Company
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as ”randomized“, no further de-
tails given.
Allocation concealment (selection bias) Low risk ”The vaccine and placebo were in a similar
liquid form, coded blindly and packed in
identical 4 mL vials“
Allocation was concealed through random-
ization to identical coded vials
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk See above.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk ”The vaccine code was opened after all
demographic, clinical, and microbiological
data were available“
Incomplete outcome data (attrition bias)
All outcomes
High risk Losses to follow-up were high (18%) for
adverse event data. Losses to follow-up for
clinical outcomes were not clearly stated
Selective reporting (reporting bias) Low risk None identified.
Other bias Low risk None identified.
Qadri 2003
Methods Study type: Randomized, safety and immunogenicity study in volunteers
Trial dates and duration: Not mentioned in the article
Surveillance: Surveillance for side-effects was carried out for 3 days after each vaccination.
The child was observed for 1 hour in the field clinic and was then allowed to return
home. The trained health workers made house to house visits within
3 hours to assess and record adverse events, thereafter home visits were made every day,
for the next 2 days
Participants Number of participants: 158
Inclusion criteria: Healthy children aged 18 to 36 months with both sexes
Exclusion criteria: History of gastrointestinal disorder, diarrhoeal illness in the past 2
weeks, febrile illness in the preceding week or antibiotic treatment for at least 7 days
prior to enrolment as well as children, weight-for-height <−2(S.D.) of the median value
of the National Centre of Health Statistics (NCHS) were not enrolled in the study
Interventions Vaccine: One 6 mL dose of vaccine consisted of 1 mg of rCTB plus 2 × 1010 CFU of
five strains of formalin-inactivated ETEC expressing CFA/I, CS1, CS2 + CS3, CS4 and
CS5 antigens each
Placebo: 1 × 1011 CFU of heat-killed E. coli K12.
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Additional details: The children enrolled in the study were received two doses of the oral
CF-BS-ETEC vaccine (lot E-009) or the placebo with a 2 week interval in the health
station of the field site
Outcomes Included in review:
• Adverse events
• Immunological response
Notes Location: Dhaka, Bangladesh
Setting: International Centre for Diarrhoeal Disease Research, Bangladesh
Source of funding:USAID(HRN-A-00-96-90005-00), the SwedishAgency forResearch
and Economic Cooperation, Sida-SAREC (1995-0069) and ICDDR,B
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random code generated by statistician (au-
thor communication)
Allocation concealment (selection bias) Low risk ”Each subject was assigned a sequential
number at the time of initial dosing, cor-
responding to numbered and randomized
set of two single-dose vials of study agent“
Allocation was concealed through random-
ization to identical coded vials
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ”The vaccine and placebo formulation ap-
peared similar“.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk ”The investigators including field staff
and laboratory personnel were completely
blinded to the identity of the study sub-
jects, whether vaccine or placebo“
Incomplete outcome data (attrition bias)
All outcomes
Low risk Follow-up was short and no losses to fol-
low-up occurred.
Selective reporting (reporting bias) Low risk None identified.
Other bias Low risk None identified.
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Methods Study type: Randomized, safety and immunogenicity study in volunteers
Trial dates and duration: Not mentioned in the article
Surveillance: Surveillance for side effects was carried out for 3 days after each vaccination.
The children were observed for 1 hour in the field clinic and were then allowed to return
home.
Local health workers made house-to-house visits within 3 hours to assess and record
adverse events, thereafter home visits were made every day for the next 2 days
Participants Number of participants: 158
Inclusion criteria: Healthy children aged 6 to 17 months living in same socioeconomic
background
Exclusion criteria: History of gastrointestinal disorder, diarrhoeal illness in the past 2
weeks, febrile illness in the preceding week or antibiotic treatment at least 7 days prior
to enrolment as well as children <−2 S.D. (weight/height) of the National Center of
Health Statistics (NCHS) were also not recruited. Children who were found to be
asymptomatically positive for any bacterial enteric pathogen including ETEC during
the screening and any participant with ETEC infection during the study period was to
be excluded
Interventions Vaccine: A quarter dose of vaccine composed of total 2.5 × 1010 CFU of five strains
of ETEC. An 1.5 mL dose contained 0.25 mg of recombinant cholera toxin B subunit
(BS) plus 0.5 × 1010 formalin-inactivated bacteria of each of five different ETEC strains
producing CFA/I, CS1, CS2, CS3, CS4, CS5 (lot E 008)
Placebo: 2.5 × 1010 CFU of heat-killed E. coli K12 bacteria
Additional details: Each two-dose (quarter dose) of vaccine regimen was given at intervals
of 2 weeks intervals
Outcomes Included in review:
• Adverse events
• Immunological response
Notes Location: Dhaka, Bangladesh
Setting: International Centre for Diarrhoeal Disease Research, Bangladesh
Source of funding:USAID(HRN-A-00-96-90005-00), the SwedishAgency forResearch
and Economic Cooperation, Sida-SAREC (2001-3970) and icddr,b
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random code generated by statistician (au-
thor communication)
Allocation concealment (selection bias) Low risk ”Randomized vials of study agents either
vaccine or placebo were supplied by the
company“
The vials were identical in appearance (au-
thor communication)
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The blinding of the study code was main-
tained throughout (author communica-
tion)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk See above.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Follow-up was short and no losses to fol-
low-up occurred.
Selective reporting (reporting bias) Low risk None identified.
Other bias Low risk None identified.
Sack 2007
Methods Study type: Randomized, natural challenge, efficacy study in travellers
Trial dates and duration: May 1998 to September 1999
Surveillance: The participants were given vials for collection of faecal samples and daily
diaries to record the presence or absence of symptoms each day during the stay, up to 28
days. The participants visited the office at least twice weekly, and turned in their diaries
weekly, at which time the diaries were reviewed with the study staff
Participants Number of participants: 685 for safety analysis and 669 for efficacy analysis
Inclusion criteria: Travellers from USA to Mexico and Guatemala and planned to stay at
least 14 days, travellers more than≥17 years of age, good health condition, US resident
with a telephone, willingness to participate and signed consent, females not pregnant
and willing to use reliable birth control during the study period
Exclusion criteria: Clinically significant acute or chronic gastrointestinal disease, any
serious medical condition, immunodeficiency, planned to use antibiotics during the trip
and recent exposure to ETEC within the past 1-year
Interventions Vaccine: 1 x 1011 formalin-killed 5 strains of enterotoxigenic E. coli expressing CFA1,
CS1, CS2, CS3, CS4 and CS5 plus 1 mg of the recombinant B-subunit of cholera toxin
Placebo: Killed non-pathogenic E. coli K12
Additional details: The participants fasted for one hour before and after vaccination. The
first dose was taken about 3 weeks before travel (acceptable range, 11 to 35 days prior
to travel) and the second dose was taken about 8 days before travel (acceptable range:
between 4 to 10 days before travel). The two doses were separated by between 7 to 21
days
Outcomes Included in review:
• ETEC diarrhoea
• Severe ETEC diarrhoea
• All-cause diarrhoea
• Any ETEC illness
• Severe ETEC illness
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• Adverse events
• Immunological response
Notes Location: USA, Mexico, and Guatemala
Setting: Vaccine Testing Unit (VTU), Johns HopkinsUniversity, Baltimore, MD, USA;
Institute of Nutrition of Central America and Panama (INCAP), Guatemala; Hospital
del Nino Morelense, Mexico; University of Gothenburg, Sweden
Source of funding: SBL VaccineAB, Stockholm, Sweden
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”The randomisationused blocks of 10 (pre-
pared by the CRO Clinical Data Care
in Lund, Sweden) to assure similar dis-
tribution throughout the study and the
blocks were stratified according to destina-
tion (Guatemalaor Mexico)“
Allocation concealment (selection bias) Low risk ”The participants were randomised to re-
ceive twodoses of the vaccine in a bicarbon-
ate citrate buffer, or an identical appearing
placebo“
”The vials of vaccine had unique study
numbers that were then used as the study
number to identify that participant. The
volunteers were considered as randomised
when they had signed the informed con-
sent“
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ”The complete randomisation list exists in
two sealed and identical copies. One was
stored at SBL Vaccin AB, and the other at
CDC in Lund“
”These envelopes were to be opened only
if there was a medical and/or ethical need
to know the vaccination code, as requested
by the DSMB“
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk See above.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses to follow-up were low (< 10%) in
each group.
Selective reporting (reporting bias) Low risk None identified.
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Other bias Low risk None identified.
Savarino 1998
Methods Study type: Randomized, safety and immunogenicity study in volunteers
Trial dates and duration: Not mentioned in the article.
Surveillance: Subjects had oral temperatures taken and underwent a standardized, struc-
tured interview on 3 consecutive days after each dose. In addition, subjects were asked
to provide 3 venous blood samples, 1 just before the first dose and 1 each 7 days after
the first and second doses
Participants Number of participants: 76
Inclusion criteria: Healthy men and women aged 21 to 45 years
Exclusion criteria: Participantswith a history of chronic gastrointestinal illness, diarrhoea,
antidiarrhoeal drug usage, febrile illness in the week before dosing or pregnancy
Interventions Vaccine: Each 4 mL dose of the ETEC/rCTB vaccine (Lot E003) contained 1 mg
rCTB plus 2 x 1010 formalin-inactivated bacteria of each of the following ETEC strains:
SBL101 (O78:H12; CFA/I; ST+); SBL104 (O25:H42; CS4+CS6); SBL105 (O167:H5;
CS5+CS6; ST+); SBL106 (O6:H16; CS1); and SBL107 (OR:H6; CS2 CS3)
Placebo: 1 × 1011 CFU of heat-killed E. coli K12 bacteria
Additional details: Subjects were offered a two dose schedule of study agent in three
rounds at intervals of 2 weeks, with fasting for at least 90 minutes before and after dosing
Outcomes Included in review:
• Adverse events
• Immunological response
Notes Location: Benha, Egypt
Setting: Cairo, Egypt.
Source of funding: Naval Medical Research and Development Command, the National
Institute of Child Health and Human Development Under Interagency Agreement (Y1-
HD-0026-01) and WHO Global Programme for Vaccines and Immunization/Vaccine
Research and Development
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”After enrollment, subjects were random-
ized to receive vaccine or placebo in a dou-
ble-blind fashion within blocks of 4 se-
quentially randomized subjects“
It was unclear if this was truly randomized.
Allocation concealment (selection bias) Low risk ”At the time of initial dosing, each sub-
ject was assigned a sequential number cor-
responding to sequentially numbered sin-
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gle-dose vials of study agent“
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as ”double blind, placebo con-
trolled“, and vaccines labelled only with
study code
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk ”The code was broken after all clinical and
laboratory evaluations were completed“
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only two subjects were excluded from the
2nd dose from placebo group because of
absenteeism or intercurrent diarrhoea
Selective reporting (reporting bias) Low risk None.
Other bias Low risk None.
Savarino 1999 (Study 1)
Methods Study type: Randomized, safety and immunogenicity study in volunteers
Trial dates and duration: June 1996
Surveillance: Subjects were observed for 30 minutes after each dose for occurrence of
immediate adverse effects. For the next 3 days after each dose, parents were asked to report
to the study centre with their child. During each visit, a trained health care provider
obtained the child’s temperature and performed a standardized, structured interview for
24 hour recall of symptoms
Participants Number of participants: 107
Inclusion criteria: Healthy Egyptian children aged between 6 to 12 years were recruited
from Benha, Egypt
Exclusion criteria: Children with a history of chronic gastrointestinal disorder, diarrhoea,
or febrile illness, or some other serious chronic illness
Interventions Vaccine: Each 4 mL dose of the ETEC/rCTB vaccine (Lot E003) contained 1 mg
rCTB plus 2 x 1010 formalin-inactivated bacteria of each of the following ETEC strains:
SBL101 (O78:H12; CFA/I; ST); SBL104 (O25:H42; CS4); SBL105 (O167:H5; CS5;
ST); SBL106 (O6:H16; CS1); and SBL107 (OR:H6; CS2 CS3)
Placebo: 1 × 1011 CFU of heat-killed E. coli K12 bacteria
Additional details: Subjects received a two-dose schedule of study agent 2 weeks apart,
fasting for at least 90 minutes before and after each dose
Outcomes Included in review:
• Adverse events
• Immunological response
Notes Location: Benha, Egypt.
Setting: US Naval Medical Research Unit No. 3, Cairo, Egypt.
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Source of funding: Naval Medical Research and Development Command, the National
Institute of Child Health and Human Development Under Interagency Agreement (Y1-
HD-0026-01) and WHO Global Programme for Vaccines and Immunization/Vaccine
Research and Development
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”Each child was assigned a sequential num-
ber corresponding to serially numbered and
randomized sets of two single-dose vials of
study agent“
Allocation concealment (selection bias) Low risk See above.
Allocation was concealed through random-
ization to identical coded vials
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ”Investigators and subjects were kept
blinded as to assignments until all clinical
and laboratory evaluations were completed
and data files were frozen“
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk See above.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only two subjects were excluded from the
2nd dose because of fever, diarrhoea, or
other intercurrent illness
Selective reporting (reporting bias) Low risk None identified.
Other bias Low risk None identified.
Savarino 1999 (Study 2)
Methods Study type: Randomized, safety and immunogenicity study in volunteers
Trial dates and duration: November to December 1996, pre-school children
Surveillance: Subjects were observed for 30 minutes after each dose for occurrence of
immediate adverse effects. For the next 3 days after each dose, parents were asked to report
to the study centre with their child. During each visit, a trained health care provider
obtained the child’s temperature and performed a standardized, structured interview for
24 hour recall of symptoms
Participants Number of participants: 106
Inclusion criteria: Healthy Egyptian children ages, both boys and girls aged between 2
to 5 years were recruited from Benha, Egypt
Exclusion criteria: Children with a history of chronic gastrointestinal disorder, diarrhoea,
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or febrile illness, or some other serious chronic illness
Interventions Vaccine: Each 4 mL dose of the ETEC/rCTB vaccine (Lot E003) contained 1 mg rCTB
plus 2x1010 formalin-inactivated bacteria of each of the following ETEC strains: SBL101
(O78:H12; CFA/I; ST); SBL104 (O25:H42; CS4); SBL105 (O167:H5; CS5; ST);
SBL106 (O6:H16; CS1); and SBL107 (OR:H6; CS2 CS3)
Placebo: 1 × 1011 CFU of heat-killed E. coli K12 bacteria.
Additional details: Subjects received a two-dose schedule of study agent 2 weeks
apart, fasting for at least 90 minutes before and after each dose
Outcomes Included in review:
• Adverse events
• Immunological response
Notes Location: Benha, Egypt
Setting: US Naval Medical Research Unit No. 3, Cairo, Egypt
Source of funding: Naval Medical Research and Development Command, the National
Institute of Child Health and Human Development Under Interagency Agreement (Y1-
HD-0026-01) and WHO Global Programme for Vaccines and Immunization/Vaccine
Research and Development
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”Each child was assigned a sequential num-
ber corresponding to serially numbered and
randomized sets of two single-dose vials of
study agent“
Allocation concealment (selection bias) Low risk See above.
Allocation was concealed through random-
ization to identical coded vials
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ”Investigators and subjects were kept
blinded as to assignments until all clinical
and laboratory evaluations were completed
and data files were frozen“
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk See above.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses to follow-up were low: Nine subjects
were excluded from the 2nd dose because
of fever, diarrhoea, or other intercurrent ill-
ness
Selective reporting (reporting bias) Low risk None identified.
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Other bias Low risk None identified.
Savarino 2002
Methods Study type: Randomized, safety and immunogenicity study in volunteers
Trial dates and duration: September to October 1997
Surveillance: Subjects were directly observed for 30minutes after each dose for immediate
adverse events. For three days after each dose parents reported daily to the study centre
with their child. At each visit a trained health worker took the child’s rectal temperature
and performed a standardized, structured interview for 24 hour recall of symptoms.
Occurrence of specific gastrointestinal symptoms and other unanticipated complaints
was ascertained
Participants Number of participants: 95
Inclusion criteria:Healthy boys and girls aged 6 to 18monthswere recruited fromBenha,
Egypt
Exclusion criteria: Children with a history of chronic gastrointestinal disorder, some
other serious chronic illness, or congenital anomaly
Interventions Vaccine: Each 4 mL dose of the ETEC/rCTB vaccine (Lot E003) contained 1 mg
rCTB plus 2 x 1010 formalin-inactivated bacteria of each of the following ETEC strains:
SBL101 (O78:H12; CFA/I; ST); SBL104 (O25:H42; CS4); SBL105 (O167:H5; CS5;
ST); SBL106 (O6:H16; CS1); and SBL107 (OR:H6; CS2 CS3)
Placebo: 1 × 1011 CFU of heat-killed E. coli K12 bacteria
Additional details: Subjects were offered a three dose schedule of study agent in three
rounds at intervals of 2 weeks, with fasting for at least 1 hour before and after dosing
Outcomes Included in review:
• Adverse events
• Immunological response
Notes Location: Benha, Egypt
Setting: US Naval Medical Research Unit Number 3, Cairo, Egypt
Source of funding: Naval Medical Research and Development Command, the National
Institute of Child Health and Human Development Under Interagency Agreement (Y1-
HD-0026-01) and WHO Global Programme for Vaccines and Immunization/Vaccine
Research and Development
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”After enrollment subjects were stratified
by age (6-month bands) and gender and
then block randomized to vaccine or con-
trol (block size, four) in a 1:1 ratio“
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Allocation concealment (selection bias) Low risk ”Within each stratum children were as-
signed a sequential number corresponding
to serially numbered and randomized sets
of three single dose vials of study agent“
Allocation was concealed through random-
ization to identical coded vials
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ”Investigators and subjects were kept
blinded as to assignments until all clinical
and laboratory evaluationswere completed,
and data files were locked“
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk See above.
Incomplete outcome data (attrition bias)
All outcomes
High risk Loss to follow-up was high: 26% of ran-
domized subjects (33/128) dropped out be-
fore receiving any dose of study agent, and
33% of subjects who received at least one
dose of study agent did not complete the
study (31/95)
Selective reporting (reporting bias) Low risk None identified.
Other bias Low risk None identified.
Scerpella 1995
Methods Study type: Randomized, natural challenge, efficacy study in travellers
Trial dates and duration: From June 1992 to July 1992
Surveillance:WC/rBS oral cholera vaccine in 502 US college students attending summer
educational programs in Mexico
Participants Number of participants: 502 healthy adults
Inclusion criteria: Full-time US residence, aged 18 and over, willingness to participate
in the study and willingness to sign the consent form
Exclusion criteria: Failure to understand the nature and plan of the study, inability
to receive adequate follow-up examinations in Mexico, unwillingness to submit serum
specimens, use of oral or parenteral antibiotics in the 7 days previous to enrolment, use of
more than two doses of anti-diarrhoeal medications in the 7 days previous to enrolment,
significant abnormalities detected by screening of the medical history and physical exam,
history of severe allergic reaction to any vaccine, and in women of childbearing age, a
positive urine pregnancy test result and nursing mothers
Interventions Vaccine: WC-rBS, I mg of purified CTB subunit together with 1X1011 inactivated V.
cholerae
Placebo: Bicarbonate buffer alone.
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Additional details: Two doses of oral vaccine given, first dose at day 0 and second days
10 days later. Both vaccine and placebo are identical in appearance
Outcomes Included in review:
• ETEC diarrhoea
• Severe ETEC diarrhoea
• All-cause diarrhoea
• Any ETEC illness
• Severe ETEC illness
• Adverse events
• Immunological response
Notes Location: Mexico
Setting: Center for Infectious Diseases of the University of Texas Health Science Center
in Houston
Source of funding: DOD; DAMD 17-90-R-0048
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as ”randomized“, but no further
details given.
Allocation concealment (selection bias) Unclear risk None described.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ”For the placebo group, the 3 rnL dose of
vaccine was not added before administra-
tion of the buffer solution. In this fashion,
study participants were blinded as to which
study group they were in“
Personnel appear to be unblinded.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessors was not de-
scribed.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses to follow-up were low. Data for 492
of 502 (98%) participants were available
for analysis
Selective reporting (reporting bias) Low risk None identified.
Other bias Low risk None identified.
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Tacket 1999
Methods Study type: Randomized, artificial challenge, efficacy study in volunteers
Trial dates and duration: Not mentioned in the article
Surveillance: Vaccine or placebo administered 3 times daily for 5 days
Artificial challenge: on day 2; post challenge follow-up for 4 days
Participants Number of participants: 20
Inclusion criteria: Healthy adults
Exclusion criteria: None mentioned
Interventions Vaccine: All participants were randomized to receive 690 mg of bovine anti-E. coli CFA
milk immunoglobulin capsule
Placebo: All participants were randomized to receive 690 mg of placebo capsule
Additional details: Vaccine or placebo were administered 3 times daily, 10 minutes after
each meal, for 5 days followed by on day 2 with an applesauce containing artificial
challenge: 1 × 108 CFU of the challenge virulent strain of E. coli E24377. Schedule dose
of vaccine or placebo was also administered 10 minutes after challenge
Outcomes Included in review:
• All cause diarrhoea
Notes Location: USA
Setting: Research Isolation Ward, Kernan Hospital, University of Maryland, Baltimore,
MD, USA
Source of funding: ImmuCell Corporation, Portland, ME
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as ”‘randomized“’, but no fur-
ther details given.
Allocation concealment (selection bias) Unclear risk None described.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The placebo consisted of an identical
preparation from non-immunized cow
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Described as ”‘double blind“’ but no fur-
ther details given.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up occurred.
Selective reporting (reporting bias) Low risk None identified.
Other bias Low risk None identified.
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Methods Study type: RCT, natural challenge, efficacy study in travellers
Trial dates and duration: Not mentioned in the article
Surveillance: Post-vaccination symptoms and adverse events were reported after both
doses. All volunteers enrolled in the study were equipped with both a daily record diary
to monitor episodes of travellers’ diarrhoea during their stay abroad and with transport
media (Portagerm® and Cary Blair tubes) for collection of stool samples in case of
diarrhoea. Travelers were instructed to hand over their travel diary and transport media
tubes immediately after return
Participants Number of participants: 128 travellers (66 placebo group and 62 ETEC vaccine group)
Inclusion criteria: Adults and children, who had signed up for a trip to tropical or
subtropical destinations (44 different countries in Africa, Asia and Latin-America) with
a duration of stay intended to last 7 to 23 days
Exclusion criteria: Not mentioned in the article
Interventions Vaccine: ETEC vaccine, containing 1mg of recombinant B-subunit of cholera toxin plus
1011 formalin-killed ETEC bacteria of five ETEC strains expressing the most common
CFAs such as CFA I, CFA II (CS1, CS2 and CS3) and CFA IV (CS4, CS5 and CS6); a
B-subunit cholera whole cell vaccine (licensed in Sweden since 1992), containing 1 mg
recombinant subunit B cholera toxin and 1011 inactivated whole cells (Inaba,Ogawa;
classical and El Tor)
Placebo: Approximately 1011 inactivated E. coli K12
Additional details: Two consecutive vaccine or placebo doses given at an interval of
between 7 to 21 days, not less than 7 days and not more than 30 days before departure
Outcomes Included in review:
• ETEC diarrhoea
• All-cause diarrhoea
• Adverse events
• Immunological response
Notes Location: Institute for Specific Prophylaxis and Tropical Medicine, University of Vienna,
Austria
Setting: Institute for Specific Prophylaxis and Tropical Medicine, University of Vienna,
Austria; Department of Medical Microbiology and Immunology, Göteborg University,
Sweden; Swedish Bacteriological Laboratory, Vaccin, Sweden
Source of funding: Not mentioned
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as ”randomized“ but no further
details given.
Allocation concealment (selection bias) Unclear risk None described.
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Described as ”double blind“ but no further
details given.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Described as ”double blind“ but no further
details given.
Incomplete outcome data (attrition bias)
All outcomes
High risk Seventy-three recruited participants (29.
2%) were excluded from the primary anal-
ysis. The reasons for these exclusions were
unclear
Selective reporting (reporting bias) Low risk None identified.
Other bias Low risk None identified.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ahmed 2006 Participants did not receive a vaccine to prevent ETEC.
Ahren 1998 No control group.
Carpenter 2006 Not described as randomized.
Clemens 2004 Randomized placebo controlled Phase III trial but published the data as a cohort study. Clinical efficacy
data are unavailable from the article
Coster 2007 Participants did not receive a vaccine to prevent ETEC.
Daley 2007 No clinical efficacy data for this vaccine is available.
Evans 1984 Not described as randomized.
Evans 1988a No control group.
Evans 1988b Not described as randomized.
Glenn 2007 No control group.
Guereña-Burgueño 2002 Not described as randomized.
Hallander 2002 No protective efficacy data against travellers’ diarrhoea
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(Continued)
Holmgren 1992 No outcomes relevant to this review.
Katz 2003 Not described as randomized.
Khan 2007 Not described as randomized.
Klipstein 1986 Not described as randomized.
Lapa 2008 No clinical efficacy data for this vaccine is available.
Levine 1982 Not described as randomized.
McKenzie 2006 No true control arm for safety and immunological data.
Qadri 2006b Participants did not receive a vaccine to prevent ETEC.
Sougioultzis 2002 Topic unrelated to ETEC vaccination.
Tacket 1994 Not described as randomized.
Turner 2006 No clinical efficacy data for this vaccine is available.
Wasserman 1993 Participants did not receive a vaccine to prevent ETEC.
Wenneras 1999 Not described as randomized.
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D A T A A N D A N A L Y S E S
Comparison 1. Cholera killed whole cell vaccine (Cholera WC-BS) versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 ETEC diarrhoea 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2 Severe ETEC diarrhoea 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3 All-cause diarrhoea 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4 Adverse events 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4.1 Any symptoms 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Gastrointestinal symptoms 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.3 Headache 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.4 Respiratory symptoms 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.5 Others 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 2. Cholera killed whole cell vaccine with recombinant B-subunit (CholeraWC-rCTB) versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 ETEC diarrhoea 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2 All-cause diarrhoea 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3 ETEC diarrhoea (Scerpella
1995a subgroup analysis
excluding cases of ETEC
occurring < 7 days after
vaccination)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Cholera WC-rCTB
versus placebo (all participants
included in denominator)
1 502 Risk Ratio (M-H, Fixed, 95% CI) 0.59 [0.24, 1.47]
3.2 Cholera WC-rCTB versus
placebo (participants who
had ETEC diarrhoea before
vaccination complete excluded
from denominator)
1 457 Risk Ratio (M-H, Fixed, 95% CI) 0.58 [0.23, 1.44]
4 Immunological response: >
4-fold increase in toxin-specific
IgG antibody responses in
serum/plasma
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
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Comparison 3. ETEC killed whole cell vaccine with recombinant cholera B-subunit (ETEC WC-rCTB) versus
placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 ETEC diarrhoea 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2 Severe ETEC diarrhoea 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3 All-cause diarrhoea 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4 Adverse events: ETEC
WC-rCTB versus placebo
(after first dose)
11 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Any symptoms 9 926 Risk Ratio (M-H, Fixed, 95% CI) 1.63 [1.34, 1.97]
4.2 Diarrhoea 9 1528 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.55, 1.40]
4.3 Abdominal pain 7 1275 Risk Ratio (M-H, Fixed, 95% CI) 1.17 [0.79, 1.73]
4.4 Loss of appetite 7 696 Risk Ratio (M-H, Fixed, 95% CI) 1.83 [1.03, 3.24]
4.5 Gas/abdominal
distension/bloating
1 158 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.6 Nausea 4 904 Risk Ratio (M-H, Fixed, 95% CI) 1.24 [0.73, 2.09]
4.7 Vomiting 9 1528 Risk Ratio (M-H, Fixed, 95% CI) 2.00 [1.16, 3.45]
4.8 Fever 7 778 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.34, 2.22]
4.9 Headache 2 154 Risk Ratio (M-H, Fixed, 95% CI) 1.46 [0.88, 2.42]
4.10 Malaise 2 154 Risk Ratio (M-H, Fixed, 95% CI) 1.77 [0.91, 3.44]
4.11 Spitting with cough 1 158 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.14, 6.92]
4.12 Others 5 1058 Risk Ratio (M-H, Fixed, 95% CI) 1.37 [0.83, 2.26]
5 Immunological response:
> 2-fold increase in
CFA/I-specific IgA antibody
response in serum/plasma
12 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6 Immunological response: >
2-fold increase in toxin-specific
IgA antibody responses in
serum/plasma
13 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
Comparison 4. Live attenuated cholera vaccine (CVD 103-HgR) versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 ETEC diarrhoea 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
2 Moderate to severe ETEC
diarrhoea
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3 All-cause diarrhoea 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
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Comparison 5. Live attenuated ETEC vaccine (PTL-003) versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 ETEC diarrhoea 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
2 Moderate to severe ETEC
diarrhoea
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3 Adverse events (after first dose) 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 Abdominal cramps/pain 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Diarrhoea 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 Gas/abdominal
distension/bloating
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.4 Gurgling/bubbling 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.5 Nausea 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.6 Loss of appetite 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.7 Vomiting 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.8 Fever 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.9 Malaise 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.10 Headache 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.11 Arthalgias/myalgias 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Immunological response: >
2-fold increase in TSA
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 6. Transcutaneous LT patch versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 ETEC diarrhoea 2 217 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.64, 1.08]
2 Moderate to severe ETEC
diarrhoea
2 217 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.59, 1.25]
3 All-cause diarrhoea 1 170 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.35, 1.42]
4 Adverse events 2 1643 Risk Ratio (M-H, Fixed, 95% CI) 3.87 [3.10, 4.84]
4.1 Rash 2 260 Risk Ratio (M-H, Fixed, 95% CI) 5.80 [3.88, 8.67]
4.2 Pruritus 2 260 Risk Ratio (M-H, Fixed, 95% CI) 4.66 [3.25, 6.68]
4.3 Vesicles 1 59 Risk Ratio (M-H, Fixed, 95% CI) 10.65 [0.62, 184.25]
4.4 Skin discoloration 2 260 Risk Ratio (M-H, Fixed, 95% CI) 9.73 [2.87, 32.92]
4.5 Fever 1 201 Risk Ratio (M-H, Fixed, 95% CI) 2.0 [0.13, 31.48]
4.6 Malaise 1 201 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.39, 3.19]
4.7 Headache 1 201 Risk Ratio (M-H, Fixed, 95% CI) 1.29 [0.59, 2.82]
4.8 Diarrhoea 1 201 Risk Ratio (M-H, Fixed, 95% CI) 1.5 [0.67, 3.38]
5 Immunological response 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 > 4-fold increase in
anti-LT specific IgA responses
in serum/plasma
2 217 Risk Ratio (M-H, Fixed, 95% CI) 43.00 [12.33, 149.
97]
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Comparison 7. Hyperimmune anti-E. coli CFA versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All-cause diarrhoea 2 45 Risk Ratio (M-H, Fixed, 95% CI) 0.51 [0.22, 1.15]
2 Adverse events 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 Anorexia 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Malaise 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 Gas 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.4 Abdominal pain 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.5 Headache 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Analysis 1.1. Comparison 1 Cholera killed whole cell vaccine (Cholera WC-BS) versus placebo, Outcome 1
ETEC diarrhoea.
Review: Vaccines for preventing enterotoxigenic Escherichia coli (ETEC) diarrhoea
Comparison: 1 Cholera killed whole cell vaccine (Cholera WC-BS) versus placebo
Outcome: 1 ETEC diarrhoea
Study or subgroup Vaccine Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Clemens 1988 (1) 6/24770 18/24842 0.33 [ 0.13, 0.84 ]
Peltola 1991 (2) 14/307 29/308 0.48 [ 0.26, 0.90 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 20 (Vaccine), 47 (Placebo)
Heterogeneity: Chi2 = 0.0, df = 0 (P<0.00001); I2 =0.0%
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours Vaccine Favours Placebo
(1) Clemens 1988a: A natural challenge study in an endemic population in Bangladesh.
(2) Peltola 1991a: A natural challenge study in people travelling from Europe to Morocco
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Analysis 1.2. Comparison 1 Cholera killed whole cell vaccine (Cholera WC-BS) versus placebo, Outcome 2
Severe ETEC diarrhoea.
Review: Vaccines for preventing enterotoxigenic Escherichia coli (ETEC) diarrhoea
Comparison: 1 Cholera killed whole cell vaccine (Cholera WC-BS) versus placebo
Outcome: 2 Severe ETEC diarrhoea
Study or subgroup Vaccine Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Clemens 1988 (1) 1/24770 7/24842 0.14 [ 0.02, 1.16 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 1 (Vaccine), 7 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Vaccine Favours Placebo
(1) Clemens 1988a: A natural challenge study in an endemic population in Bangladesh.
Analysis 1.3. Comparison 1 Cholera killed whole cell vaccine (Cholera WC-BS) versus placebo, Outcome 3
All-cause diarrhoea.
Review: Vaccines for preventing enterotoxigenic Escherichia coli (ETEC) diarrhoea
Comparison: 1 Cholera killed whole cell vaccine (Cholera WC-BS) versus placebo
Outcome: 3 All-cause diarrhoea
Study or subgroup Vaccine Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Peltola 1991 (1) 72/307 94/308 0.77 [ 0.59, 1.00 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 72 (Vaccine), 94 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours Vaccine Favours Placebo
(1) Peltola 1991a: A natural challenge study in people travelling from Europe to Morocco
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Analysis 1.4. Comparison 1 Cholera killed whole cell vaccine (Cholera WC-BS) versus placebo, Outcome 4
Adverse events.
Review: Vaccines for preventing enterotoxigenic Escherichia coli (ETEC) diarrhoea
Comparison: 1 Cholera killed whole cell vaccine (Cholera WC-BS) versus placebo
Outcome: 4 Adverse events
Study or subgroup Vaccine Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Any symptoms
Peltola 1991 (1) 85/243 118/265 0.79 [ 0.63, 0.98 ]
2 Gastrointestinal symptoms
Peltola 1991 59/243 88/265 0.73 [ 0.55, 0.97 ]
3 Headache
Peltola 1991 10/243 11/265 0.99 [ 0.43, 2.29 ]
4 Respiratory symptoms
Peltola 1991 12/243 15/265 0.87 [ 0.42, 1.83 ]
5 Others
Peltola 1991 2/243 3/265 0.73 [ 0.12, 4.31 ]
0.01 0.1 1 10 100
Favours Vaccine Favours Placebo
(1) Peltola 1991a: A natural challenge study in people travelling from Europe to Morocco
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Analysis 2.1. Comparison 2 Cholera killed whole cell vaccine with recombinant B-subunit (Cholera WC-
rCTB) versus placebo, Outcome 1 ETEC diarrhoea.
Review: Vaccines for preventing enterotoxigenic Escherichia coli (ETEC) diarrhoea
Comparison: 2 Cholera killed whole cell vaccine with recombinant B-subunit (Cholera WC-rCTB) versus placebo
Outcome: 1 ETEC diarrhoea
Study or subgroup Vaccine Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Scerpella 1995 (1) 36/250 39/252 0.93 [ 0.61, 1.41 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 36 (Vaccine), 39 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours Vaccine Favours Placebo
(1) Scerpella 1995a: A natural challenge study in people travelling from USA to Mexico.
Analysis 2.2. Comparison 2 Cholera killed whole cell vaccine with recombinant B-subunit (Cholera WC-
rCTB) versus placebo, Outcome 2 All-cause diarrhoea.
Review: Vaccines for preventing enterotoxigenic Escherichia coli (ETEC) diarrhoea
Comparison: 2 Cholera killed whole cell vaccine with recombinant B-subunit (Cholera WC-rCTB) versus placebo
Outcome: 2 All-cause diarrhoea
Study or subgroup Vaccine Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Scerpella 1995 (1) 128/250 124/252 1.04 [ 0.87, 1.24 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 128 (Vaccine), 124 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours Vaccine Favours Placebo
(1) Scerpella 1995a: A natural challenge study in people travelling from USA to Mexico.
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Analysis 2.3. Comparison 2 Cholera killed whole cell vaccine with recombinant B-subunit (Cholera WC-
rCTB) versus placebo, Outcome 3 ETEC diarrhoea (Scerpella 1995a subgroup analysis excluding cases of
ETEC occurring < 7 days after vaccination).
Review: Vaccines for preventing enterotoxigenic Escherichia coli (ETEC) diarrhoea
Comparison: 2 Cholera killed whole cell vaccine with recombinant B-subunit (Cholera WC-rCTB) versus placebo
Outcome: 3 ETEC diarrhoea (Scerpella 1995a subgroup analysis excluding cases of ETEC occurring < 7 days after vaccination)
Study or subgroup Vaccine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Cholera WC-rCTB versus placebo (all participants included in denominator)
Scerpella 1995 (1) 7/250 12/252 100.0 % 0.59 [ 0.24, 1.47 ]
Subtotal (95% CI) 250 252 100.0 % 0.59 [ 0.24, 1.47 ]
Total events: 7 (Vaccine), 12 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.14 (P = 0.26)
2 Cholera WC-rCTB versus placebo (participants who had ETEC diarrhoea before vaccination complete excluded from denominator)
Scerpella 1995 7/230 12/227 100.0 % 0.58 [ 0.23, 1.44 ]
Subtotal (95% CI) 230 227 100.0 % 0.58 [ 0.23, 1.44 ]
Total events: 7 (Vaccine), 12 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.18 (P = 0.24)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.97), I2 =0.0%
0.05 0.2 1 5 20
Favours Vaccine Favours Placebo
(1) Scerpella 1995a: These data present only the cases of ETEC diarrhoea that occurred more than seven days after the second vaccine dose
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Analysis 2.4. Comparison 2 Cholera killed whole cell vaccine with recombinant B-subunit (Cholera WC-
rCTB) versus placebo, Outcome 4 Immunological response: > 4-fold increase in toxin-specific IgG antibody
responses in serum/plasma.
Review: Vaccines for preventing enterotoxigenic Escherichia coli (ETEC) diarrhoea
Comparison: 2 Cholera killed whole cell vaccine with recombinant B-subunit (Cholera WC-rCTB) versus placebo
Outcome: 4 Immunological response: > 4-fold increase in toxin-specific IgG antibody responses in serum/plasma
Study or subgroup Vaccine Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Scerpella 1995 (1) 117/135 12/146 10.54 [ 6.11, 18.20 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 117 (Vaccine), 12 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours Placebo Favours Vaccine
(1) Scerpella 1995a: An efficacy study in people travelling from USA to Mexico.
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Analysis 3.1. Comparison 3 ETEC killed whole cell vaccine with recombinant cholera B-subunit (ETEC
WC-rCTB) versus placebo, Outcome 1 ETEC diarrhoea.
Review: Vaccines for preventing enterotoxigenic Escherichia coli (ETEC) diarrhoea
Comparison: 3 ETEC killed whole cell vaccine with recombinant cholera B-subunit (ETEC WC-rCTB) versus placebo
Outcome: 1 ETEC diarrhoea
Study or subgroup Vaccine Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sack 2007 (1) 11/330 15/341 0.76 [ 0.35, 1.63 ]
Wiedermann 2000 (2) 1/62 5/66 0.21 [ 0.03, 1.77 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 12 (Vaccine), 20 (Placebo)
Heterogeneity: Chi2 = 0.0, df = 0 (P<0.00001); I2 =0.0%
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours Vaccine Favours Placebo
(1) Sack 2007a: A natural challenge study in people travelling from USA to Mexico, Guatemala.
(2) Wiederman 2000a: A natural challenge study in people travelling from Austria to 44 different countries in Latin America, Africa and Asia.
Analysis 3.2. Comparison 3 ETEC killed whole cell vaccine with recombinant cholera B-subunit (ETEC
WC-rCTB) versus placebo, Outcome 2 Severe ETEC diarrhoea.
Review: Vaccines for preventing enterotoxigenic Escherichia coli (ETEC) diarrhoea
Comparison: 3 ETEC killed whole cell vaccine with recombinant cholera B-subunit (ETEC WC-rCTB) versus placebo
Outcome: 2 Severe ETEC diarrhoea
Study or subgroup Vaccine Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sack 2007 (1) 2/330 9/341 0.23 [ 0.05, 1.05 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 2 (Vaccine), 9 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Vaccine Favours Placebo
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(1) Sack 2007a: A natural challenge study in people travelling from USA to Mexico, Guatemala.
Analysis 3.3. Comparison 3 ETEC killed whole cell vaccine with recombinant cholera B-subunit (ETEC
WC-rCTB) versus placebo, Outcome 3 All-cause diarrhoea.
Review: Vaccines for preventing enterotoxigenic Escherichia coli (ETEC) diarrhoea
Comparison: 3 ETEC killed whole cell vaccine with recombinant cholera B-subunit (ETEC WC-rCTB) versus placebo
Outcome: 3 All-cause diarrhoea
Study or subgroup Vaccine Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sack 2007 (1) 108/330 98/341 1.14 [ 0.91, 1.43 ]
Wiedermann 2000 (2) 15/62 14/66 1.14 [ 0.60, 2.16 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 123 (Vaccine), 112 (Placebo)
Heterogeneity: Chi2 = 0.0, df = 0 (P<0.00001); I2 =0.0%
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours Vaccine Favours Placebo
(1) Sack 2007a: A natural challenge study in people travelling from USA to Mexico, Guatemala.
(2) Wiederman 2000a: A natural challenge study in people travelling from Austria to 44 different countries in Latin America, Africa and Asia.
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Analysis 3.4. Comparison 3 ETEC killed whole cell vaccine with recombinant cholera B-subunit (ETEC
WC-rCTB) versus placebo, Outcome 4 Adverse events: ETECWC-rCTB versus placebo (after first dose).
Review: Vaccines for preventing enterotoxigenic Escherichia coli (ETEC) diarrhoea
Comparison: 3 ETEC killed whole cell vaccine with recombinant cholera B-subunit (ETEC WC-rCTB) versus placebo
Outcome: 4 Adverse events: ETEC WC-rCTB versus placebo (after first dose)
Study or subgroup Vaccine Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Any symptoms
Cohen 2000 (Study 1) (1) 21/33 16/31 1.23 [ 0.80, 1.89 ]
Cohen 2000 (Study 2) 30/45 21/45 1.43 [ 0.98, 2.08 ]
Jertborn 1998 (2) 4/20 2/19 1.90 [ 0.39, 9.20 ]
Qadri 2003 (3) 14/79 12/79 1.17 [ 0.58, 2.36 ]
Qadri 2006a (4) 7/79 2/79 3.50 [ 0.75, 16.33 ]
Savarino 1998 (5) 16/38 8/38 2.00 [ 0.97, 4.11 ]
Savarino 1999 (Study 1) (6) 5/52 10/55 0.53 [ 0.19, 1.44 ]
Savarino 1999 (Study 2) 10/54 8/52 1.20 [ 0.52, 2.81 ]
Wiedermann 2000 (7) 56/62 22/66 2.71 [ 1.91, 3.85 ]
Subtotal (95% CI) 462 464 1.63 [ 1.34, 1.97 ]
Total events: 163 (Vaccine), 101 (Placebo)
Heterogeneity: Chi2 = 17.66, df = 8 (P = 0.02); I2 =55%
Test for overall effect: Z = 4.96 (P < 0.00001)
2 Diarrhoea
Cohen 2000 (Study 1) 0/33 2/31 0.19 [ 0.01, 3.77 ]
Cohen 2000 (Study 2) 0/45 2/45 0.20 [ 0.01, 4.05 ]
Qadri 2003 3/79 3/79 1.00 [ 0.21, 4.80 ]
Qadri 2006a 2/79 1/79 2.00 [ 0.19, 21.61 ]
Sack 2007 (8) 11/339 11/335 0.99 [ 0.43, 2.25 ]
Savarino 1998 0/38 1/38 0.33 [ 0.01, 7.93 ]
Savarino 1999 (Study 1) 2/52 2/55 1.06 [ 0.15, 7.24 ]
Savarino 1999 (Study 2) 2/54 2/52 0.96 [ 0.14, 6.59 ]
Savarino 2002 (9) 9/48 9/47 0.98 [ 0.43, 2.25 ]
Subtotal (95% CI) 767 761 0.87 [ 0.55, 1.40 ]
Total events: 29 (Vaccine), 33 (Placebo)
Heterogeneity: Chi2 = 2.98, df = 8 (P = 0.94); I2 =0.0%
0.005 0.1 1 10 200
Favours Vaccine Favours Placebo
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(. . . Continued)
Study or subgroup Vaccine Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for overall effect: Z = 0.56 (P = 0.57)
3 Abdominal pain
Cohen 2000 (Study 1) 12/33 8/31 1.41 [ 0.67, 2.98 ]
Cohen 2000 (Study 2) 15/45 8/45 1.88 [ 0.88, 3.98 ]
Qadri 2003 0/79 0/79 0.0 [ 0.0, 0.0 ]
Sack 2007 7/339 9/335 0.77 [ 0.29, 2.04 ]
Savarino 1998 7/38 3/38 2.33 [ 0.65, 8.36 ]
Savarino 1999 (Study 1) 2/52 6/55 0.35 [ 0.07, 1.67 ]
Savarino 1999 (Study 2) 2/54 4/52 0.48 [ 0.09, 2.52 ]
Subtotal (95% CI) 640 635 1.17 [ 0.79, 1.73 ]
Total events: 45 (Vaccine), 38 (Placebo)
Heterogeneity: Chi2 = 6.98, df = 5 (P = 0.22); I2 =28%
Test for overall effect: Z = 0.77 (P = 0.44)
4 Loss of appetite
Cohen 2000 (Study 1) 6/33 2/31 2.82 [ 0.61, 12.93 ]
Cohen 2000 (Study 2) 10/45 5/45 2.00 [ 0.74, 5.39 ]
Qadri 2003 2/79 1/79 2.00 [ 0.19, 21.61 ]
Savarino 1998 4/38 2/38 2.00 [ 0.39, 10.28 ]
Savarino 1999 (Study 1) 0/52 2/55 0.21 [ 0.01, 4.30 ]
Savarino 1999 (Study 2) 3/54 2/52 1.44 [ 0.25, 8.30 ]
Savarino 2002 5/48 2/47 2.45 [ 0.50, 12.00 ]
Subtotal (95% CI) 349 347 1.83 [ 1.03, 3.24 ]
Total events: 30 (Vaccine), 16 (Placebo)
Heterogeneity: Chi2 = 2.53, df = 6 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 2.06 (P = 0.040)
5 Gas/abdominal distension/bloating
Qadri 2006a 0/79 0/79 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 79 79 0.0 [ 0.0, 0.0 ]
Total events: 0 (Vaccine), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
6 Nausea
Cohen 2000 (Study 1) 4/33 5/31 0.75 [ 0.22, 2.55 ]
Cohen 2000 (Study 2) 7/45 5/45 1.40 [ 0.48, 4.08 ]
Sack 2007 13/339 11/335 1.17 [ 0.53, 2.57 ]
Savarino 1998 5/38 2/38 2.50 [ 0.52, 12.10 ]
Subtotal (95% CI) 455 449 1.24 [ 0.73, 2.09 ]
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Study or subgroup Vaccine Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 29 (Vaccine), 23 (Placebo)
Heterogeneity: Chi2 = 1.48, df = 3 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.80 (P = 0.42)
7 Vomiting
Cohen 2000 (Study 1) 0/33 1/31 0.31 [ 0.01, 7.42 ]
Cohen 2000 (Study 2) 2/45 0/45 5.00 [ 0.25, 101.31 ]
Qadri 2003 3/79 2/79 1.50 [ 0.26, 8.73 ]
Qadri 2006a 4/79 0/79 9.00 [ 0.49, 164.43 ]
Sack 2007 8/339 1/335 7.91 [ 0.99, 62.86 ]
Savarino 1998 1/38 0/38 3.00 [ 0.13, 71.40 ]
Savarino 1999 (Study 1) 0/52 1/55 0.35 [ 0.01, 8.46 ]
Savarino 1999 (Study 2) 3/54 2/52 1.44 [ 0.25, 8.30 ]
Savarino 2002 12/48 8/47 1.47 [ 0.66, 3.27 ]
Subtotal (95% CI) 767 761 2.00 [ 1.16, 3.45 ]
Total events: 33 (Vaccine), 15 (Placebo)
Heterogeneity: Chi2 = 6.41, df = 8 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 2.49 (P = 0.013)
8 Fever
Cohen 2000 (Study 1) 1/33 0/31 2.82 [ 0.12, 66.82 ]
Cohen 2000 (Study 2) 0/45 0/45 0.0 [ 0.0, 0.0 ]
Qadri 2003 1/79 3/79 0.33 [ 0.04, 3.14 ]
Qadri 2006a 0/79 1/79 0.33 [ 0.01, 8.06 ]
Savarino 1999 (Study 1) 0/52 0/55 0.0 [ 0.0, 0.0 ]
Savarino 1999 (Study 2) 2/54 1/52 1.93 [ 0.18, 20.60 ]
Savarino 2002 3/48 3/47 0.98 [ 0.21, 4.61 ]
Subtotal (95% CI) 390 388 0.87 [ 0.34, 2.22 ]
Total events: 7 (Vaccine), 8 (Placebo)
Heterogeneity: Chi2 = 2.04, df = 4 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.29 (P = 0.77)
9 Headache
Cohen 2000 (Study 1) 12/33 8/31 1.41 [ 0.67, 2.98 ]
Cohen 2000 (Study 2) 15/45 10/45 1.50 [ 0.76, 2.98 ]
Subtotal (95% CI) 78 76 1.46 [ 0.88, 2.42 ]
Total events: 27 (Vaccine), 18 (Placebo)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 1.46 (P = 0.14)
10 Malaise
0.005 0.1 1 10 200
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Study or subgroup Vaccine Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cohen 2000 (Study 1) 8/33 5/31 1.50 [ 0.55, 4.10 ]
Cohen 2000 (Study 2) 12/45 6/45 2.00 [ 0.82, 4.86 ]
Subtotal (95% CI) 78 76 1.77 [ 0.91, 3.44 ]
Total events: 20 (Vaccine), 11 (Placebo)
Heterogeneity: Chi2 = 0.17, df = 1 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 1.69 (P = 0.092)
11 Spitting with cough
Qadri 2003 2/79 2/79 1.00 [ 0.14, 6.92 ]
Subtotal (95% CI) 79 79 1.00 [ 0.14, 6.92 ]
Total events: 2 (Vaccine), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
12 Others
Sack 2007 10/339 7/335 1.41 [ 0.54, 3.66 ]
Savarino 1998 9/38 7/38 1.29 [ 0.53, 3.10 ]
Savarino 1999 (Study 1) 2/52 4/55 0.53 [ 0.10, 2.77 ]
Savarino 1999 (Study 2) 5/54 1/52 4.81 [ 0.58, 39.83 ]
Savarino 2002 7/48 5/47 1.37 [ 0.47, 4.02 ]
Subtotal (95% CI) 531 527 1.37 [ 0.83, 2.26 ]
Total events: 33 (Vaccine), 24 (Placebo)
Heterogeneity: Chi2 = 2.65, df = 4 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 1.23 (P = 0.22)
Test for subgroup differences: Chi2 = 11.00, df = 10 (P = 0.36), I2 =9%
0.005 0.1 1 10 200
Favours Vaccine Favours Placebo
(1) Cohen 2000: A safety study in adults in Israel
(2) Jertborn 1998: A safety study in adult swedish volunteers
(3) Qadri 2003a: A safety study in children aged 18-36 months in Bangladesh
(4) Qadri 2006b: A safety study in children aged 6-17 months in Bangladesh
(5) Savarino 1998a: A safety study in adults in Egypt
(6) Savarino 1999: A safety study in children aged 6-12 years in Egypt
(7) Wiederman 2000a: A natural challenge study in people travelling from Austria to 44 different countries in Latin America, Africa and Asia.
(8) Sack 2007a: A natural challenge study in people travelling from USA to Mexico, Guatemala.
(9) Savarino 2002a: A safety study in children aged 6-18 months in Egypt
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Analysis 3.5. Comparison 3 ETEC killed whole cell vaccine with recombinant cholera B-subunit (ETEC
WC-rCTB) versus placebo, Outcome 5 Immunological response: > 2-fold increase in CFA/I-specific IgA
antibody response in serum/plasma.
Review: Vaccines for preventing enterotoxigenic Escherichia coli (ETEC) diarrhoea
Comparison: 3 ETEC killed whole cell vaccine with recombinant cholera B-subunit (ETEC WC-rCTB) versus placebo
Outcome: 5 Immunological response: > 2-fold increase in CFA/I-specific IgA antibody response in serum/plasma
Study or subgroup Vaccine Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cohen 2000 (Study 1) (1) 8/18 1/12 5.33 [ 0.76, 37.35 ]
Cohen 2000 (Study 2) 9/35 1/40 10.29 [ 1.37, 77.19 ]
Hall 2001 (Study 1) (2) 26/38 2/35 11.97 [ 3.06, 46.79 ]
Hall 2001 (Study 2) (3) 49/51 6/54 8.65 [ 4.06, 18.42 ]
Hall 2001 (Study 3) (4) 41/47 5/46 8.03 [ 3.48, 18.49 ]
Jertborn 2001 (5) 16/19 0/12 21.45 [ 1.41, 327.40 ]
Qadri 2003 (6) 58/79 13/79 4.46 [ 2.67, 7.46 ]
Qadri 2006a (7) 47/79 4/79 11.75 [ 4.45, 31.06 ]
Savarino 1998 (8) 15/16 4/16 3.75 [ 1.59, 8.84 ]
Savarino 1999 (Study 1) (9) 16/16 2/16 6.60 [ 2.09, 20.80 ]
Savarino 1999 (Study 2) (10) 18/19 1/10 9.47 [ 1.47, 61.00 ]
Savarino 2002 (11) 22/36 5/28 3.42 [ 1.48, 7.90 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 325 (Vaccine), 44 (Placebo)
Heterogeneity: Chi2 = 0.0, df = 0 (P<0.00001); I2 =0.0%
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
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(1) Cohen 2000: A safety and immunogenicity study in adults in Israel
(2) Hall 2001 (Study 1): A safety and immunogenicity study in adults in Egypt
(3) Hall 2001 (Study 2): A safety and immunogenicity study in children aged 6-12 years in Egypt
(4) Hall 2001 (Study 2): A safety and immunogenicity study in children aged 2-5 years in Egypt
(5) Jertborn 2001: An immunogenicity study in adults in Sweden
(6) Qadri 2003a: A safety and immunogenicity study in children aged 18-36 months in Bangladesh
(7) Qadri 2006b: A safety and immunogenicity study in children aged 6-17 months in Bangladesh
(8) Savarino 1998a: A safety and immunogenicity study in adults in Egypt
(9) Savarino 1999 (Study 1): A safety and immunogenicity study in children aged 6-12 years in Egypt
(10) Savarino 1999 (Study 2): A safety and immunogenicity study in children aged 2 to 5 years in Egypt
(11) Savarino 2002a: A safety and immunogenicity study in children aged 6-18 months in Egypt
Analysis 3.6. Comparison 3 ETEC killed whole cell vaccine with recombinant cholera B-subunit (ETEC
WC-rCTB) versus placebo, Outcome 6 Immunological response: > 2-fold increase in toxin-specific IgA
antibody responses in serum/plasma.
Review: Vaccines for preventing enterotoxigenic Escherichia coli (ETEC) diarrhoea
Comparison: 3 ETEC killed whole cell vaccine with recombinant cholera B-subunit (ETEC WC-rCTB) versus placebo
Outcome: 6 Immunological response: > 2-fold increase in toxin-specific IgA antibody responses in serum/plasma
Study or subgroup Vaccine Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cohen 2000 (Study 1) (1) 14/28 2/23 5.75 [ 1.45, 22.74 ]
Cohen 2000 (Study 2) 24/35 2/40 13.71 [ 3.49, 53.93 ]
Hall 2001 (Study 1) (2) 36/38 1/35 33.16 [ 4.80, 229.18 ]
Hall 2001 (Study 2) (3) 51/51 8/54 6.41 [ 3.45, 11.90 ]
Hall 2001 (Study 3) (4) 45/47 4/46 11.01 [ 4.31, 28.14 ]
Qadri 2003 (5) 71/79 24/79 2.96 [ 2.10, 4.16 ]
Qadri 2006a (6) 77/79 16/79 4.81 [ 3.10, 7.46 ]
Sack 2007 (7) 31/43 0/42 61.57 [ 3.89, 974.64 ]
Savarino 1998 (8) 16/16 4/16 3.67 [ 1.65, 8.13 ]
0.001 0.01 0.1 1 10 100 1000
Favours Placebo Favours Vaccine
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Study or subgroup Vaccine Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Savarino 1999 (Study 1) (9) 52/52 8/55 6.53 [ 3.51, 12.13 ]
Savarino 1999 (Study 2) (10) 49/50 4/49 12.01 [ 4.69, 30.73 ]
Savarino 2002 (11) 35/36 13/28 2.09 [ 1.40, 3.13 ]
Wiedermann 2000 (12) 56/62 22/66 2.71 [ 1.91, 3.85 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 557 (Vaccine), 108 (Placebo)
Heterogeneity: Chi2 = 0.0, df = 0 (P<0.00001); I2 =0.0%
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours Placebo Favours Vaccine
(1) Cohen 2000: A safety and immunogenicity study in adults in Israel
(2) Hall 2001 (Study 1): A safety and immunogenicity study in adults in Egypt
(3) Hall 2001 (Study 2): A safety and immunogenicity study in children aged 6-12 years in Egypt
(4) Hall 2001 (Study 2): A safety and immunogenicity study in children aged 2-5 years in Egypt
(5) Qadri 2003a: A safety and immunogenicity study in children aged 18-36 months in Bangladesh
(6) Qadri 2006b: A safety and immunogenicity study in children aged 6-17 months in Bangladesh
(7) Sack 2007a: An efficacy study in Adults from the USA travelling to Mexico and Guatemala
(8) Savarino 1998a: A safety and immunogenicity study in adults in Egypt
(9) Savarino 1999 (Study 1): A safety and immunogenicity study in children aged 6-12 years in Egypt
(10) Savarino 1999 (Study 2): A safety and immunogenicity study in children aged 2 to 5 years in Egypt
(11) Savarino 2002a: A safety and immunogenicity study in children aged 6-18 months in Egypt
(12) Wiederman 2000a: An efficacy study in people travelling from Austria to 44 different countries in Latin America, Africa and Asia.
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Analysis 4.1. Comparison 4 Live attenuated cholera vaccine (CVD 103-HgR) versus placebo, Outcome 1
ETEC diarrhoea.
Review: Vaccines for preventing enterotoxigenic Escherichia coli (ETEC) diarrhoea
Comparison: 4 Live attenuated cholera vaccine (CVD 103-HgR) versus placebo
Outcome: 1 ETEC diarrhoea
Study or subgroup Vaccine Placebo Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Leyten 2005 (1) 10/69 7/65 1.35 [ 0.54, 3.33 ]
0.01 0.1 1 10 100
Favours Vaccine Favours Placebo
(1) Leyten 2005a: A natural challenge study in Dutch adults travelling to Indonesia, Thailand, India or West Africa.
Analysis 4.2. Comparison 4 Live attenuated cholera vaccine (CVD 103-HgR) versus placebo, Outcome 2
Moderate to severe ETEC diarrhoea.
Review: Vaccines for preventing enterotoxigenic Escherichia coli (ETEC) diarrhoea
Comparison: 4 Live attenuated cholera vaccine (CVD 103-HgR) versus placebo
Outcome: 2 Moderate to severe ETEC diarrhoea
Study or subgroup Vaccine Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Leyten 2005 (1) 9/69 6/65 1.41 [ 0.53, 3.75 ]
0.001 0.01 0.1 1 10 100 1000
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(1) Leyten 2005a: A natural challenge study in Dutch adults travelling to Indonesia, Thailand, India or West Africa.
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Analysis 4.3. Comparison 4 Live attenuated cholera vaccine (CVD 103-HgR) versus placebo, Outcome 3
All-cause diarrhoea.
Review: Vaccines for preventing enterotoxigenic Escherichia coli (ETEC) diarrhoea
Comparison: 4 Live attenuated cholera vaccine (CVD 103-HgR) versus placebo
Outcome: 3 All-cause diarrhoea
Study or subgroup Vaccine Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Leyten 2005 (1) 36/69 30/65 1.13 [ 0.80, 1.60 ]
0.01 0.1 1 10 100
Favours Vaccine Favours Placebo
(1) Leyten 2005a: A natural challenge study in Dutch adults travelling to Indonesia, Thailand, India or West Africa.
Analysis 5.1. Comparison 5 Live attenuated ETEC vaccine (PTL-003) versus placebo, Outcome 1 ETEC
diarrhoea.
Review: Vaccines for preventing enterotoxigenic Escherichia coli (ETEC) diarrhoea
Comparison: 5 Live attenuated ETEC vaccine (PTL-003) versus placebo
Outcome: 1 ETEC diarrhoea
Study or subgroup Vaccine Placebo Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
McKenzie 2008 (1) 14/17 13/16 1.01 [ 0.73, 1.40 ]
0.01 0.1 1 10 100
Favours Vaccine Favours Placebo
(1) McKenzie 2008: An artifical challenge study in North American adult volunteers.
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Analysis 5.2. Comparison 5 Live attenuated ETEC vaccine (PTL-003) versus placebo, Outcome 2 Moderate
to severe ETEC diarrhoea.
Review: Vaccines for preventing enterotoxigenic Escherichia coli (ETEC) diarrhoea
Comparison: 5 Live attenuated ETEC vaccine (PTL-003) versus placebo
Outcome: 2 Moderate to severe ETEC diarrhoea
Study or subgroup Vaccine Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
McKenzie 2008 (1) 12/17 11/16 1.03 [ 0.65, 1.61 ]
0.001 0.01 0.1 1 10 100 1000
Favours Vaccine Favours Placebo
(1) McKenzie 2008: An artifical challenge study in North American adult volunteers.
Analysis 5.3. Comparison 5 Live attenuated ETEC vaccine (PTL-003) versus placebo, Outcome 3 Adverse
events (after first dose).
Review: Vaccines for preventing enterotoxigenic Escherichia coli (ETEC) diarrhoea
Comparison: 5 Live attenuated ETEC vaccine (PTL-003) versus placebo
Outcome: 3 Adverse events (after first dose)
Study or subgroup Vaccine Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Abdominal cramps/pain
McKenzie 2008 (1) 0/20 2/19 0.19 [ 0.01, 3.73 ]
2 Diarrhoea
McKenzie 2008 1/20 2/19 0.48 [ 0.05, 4.82 ]
3 Gas/abdominal distension/bloating
McKenzie 2008 4/20 4/19 0.95 [ 0.28, 3.27 ]
4 Gurgling/bubbling
McKenzie 2008 1/20 1/19 0.95 [ 0.06, 14.13 ]
5 Nausea
McKenzie 2008 3/20 3/19 0.95 [ 0.22, 4.14 ]
6 Loss of appetite
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Study or subgroup Vaccine Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
McKenzie 2008 1/20 3/19 0.32 [ 0.04, 2.79 ]
7 Vomiting
McKenzie 2008 1/20 0/19 2.86 [ 0.12, 66.11 ]
8 Fever
McKenzie 2008 0/20 0/19 0.0 [ 0.0, 0.0 ]
9 Malaise
McKenzie 2008 1/20 7/19 0.14 [ 0.02, 1.00 ]
10 Headache
McKenzie 2008 3/20 3/19 0.95 [ 0.22, 4.14 ]
11 Arthalgias/myalgias
McKenzie 2008 1/20 2/19 0.48 [ 0.05, 4.82 ]
0.01 0.1 1 10 100
Favours Vaccine Favours Placebo
(1) McKenzie 2008: An artifical challenge study in North American adult volunteers.
Analysis 5.4. Comparison 5 Live attenuated ETEC vaccine (PTL-003) versus placebo, Outcome 4
Immunological response: > 2-fold increase in TSA.
Review: Vaccines for preventing enterotoxigenic Escherichia coli (ETEC) diarrhoea
Comparison: 5 Live attenuated ETEC vaccine (PTL-003) versus placebo
Outcome: 4 Immunological response: > 2-fold increase in TSA
Study or subgroup Vaccine Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
McKenzie 2008 (1) 1/17 1/16 0.94 [ 0.06, 13.82 ]
0.01 0.1 1 10 100
Favours Placebo Favours Vaccine
(1) McKenzie 2008: An artifical challenge study in North American adult volunteers.
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Analysis 6.1. Comparison 6 Transcutaneous LT patch versus placebo, Outcome 1 ETEC diarrhoea.
Review: Vaccines for preventing enterotoxigenic Escherichia coli (ETEC) diarrhoea
Comparison: 6 Transcutaneous LT patch versus placebo
Outcome: 1 ETEC diarrhoea
Study or subgroup Vaccine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Frech 2008 (1) 3/59 11/111 24.6 % 0.51 [ 0.15, 1.77 ]
McKenzie 2007 (2) 25/27 20/20 75.4 % 0.93 [ 0.82, 1.07 ]
Total (95% CI) 86 131 100.0 % 0.83 [ 0.64, 1.08 ]
Total events: 28 (Vaccine), 31 (Placebo)
Heterogeneity: Chi2 = 3.53, df = 1 (P = 0.06); I2 =72%
Test for overall effect: Z = 1.40 (P = 0.16)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Vaccine Favours Placebo
(1) Frech 2008: A natural challenge study in American adults travelling to Mexico and Guatemala.
(2) McKenzie 2007a: An artificial challenge study in healthy adult volunteers in the USA.
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Analysis 6.2. Comparison 6 Transcutaneous LT patch versus placebo, Outcome 2 Moderate to severe ETEC
diarrhoea.
Review: Vaccines for preventing enterotoxigenic Escherichia coli (ETEC) diarrhoea
Comparison: 6 Transcutaneous LT patch versus placebo
Outcome: 2 Moderate to severe ETEC diarrhoea
Study or subgroup Vaccine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Frech 2008 (1) 2/59 11/111 30.7 % 0.34 [ 0.08, 1.49 ]
McKenzie 2007 (2) 22/27 15/20 69.3 % 1.09 [ 0.80, 1.48 ]
Total (95% CI) 86 131 100.0 % 0.86 [ 0.59, 1.25 ]
Total events: 24 (Vaccine), 26 (Placebo)
Heterogeneity: Chi2 = 3.72, df = 1 (P = 0.05); I2 =73%
Test for overall effect: Z = 0.80 (P = 0.42)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Vaccine Favours Placebo
(1) Frech 2008: A natural challenge study in American adults travelling to Mexico and Guatemala.
(2) McKenzie 2007a: An artificial challenge study in healthy adult volunteers in the USA.
Analysis 6.3. Comparison 6 Transcutaneous LT patch versus placebo, Outcome 3 All-cause diarrhoea.
Review: Vaccines for preventing enterotoxigenic Escherichia coli (ETEC) diarrhoea
Comparison: 6 Transcutaneous LT patch versus placebo
Outcome: 3 All-cause diarrhoea
Study or subgroup Vaccine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Frech 2008 (1) 9/59 24/111 100.0 % 0.71 [ 0.35, 1.42 ]
Total (95% CI) 59 111 100.0 % 0.71 [ 0.35, 1.42 ]
Total events: 9 (Vaccine), 24 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.33)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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(1) Frech 2008: A natural challenge study in American adults travelling to Mexico and Guatemala.
Analysis 6.4. Comparison 6 Transcutaneous LT patch versus placebo, Outcome 4 Adverse events.
Review: Vaccines for preventing enterotoxigenic Escherichia coli (ETEC) diarrhoea
Comparison: 6 Transcutaneous LT patch versus placebo
Outcome: 4 Adverse events
Study or subgroup Vaccine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Rash
Frech 2008 (1) 43/67 2/134 2.2 % 43.00 [ 10.74, 172.14 ]
McKenzie 2007 (2) 30/30 13/29 22.7 % 2.19 [ 1.47, 3.26 ]
Subtotal (95% CI) 97 163 24.9 % 5.80 [ 3.88, 8.67 ]
Total events: 73 (Vaccine), 15 (Placebo)
Heterogeneity: Chi2 = 31.08, df = 1 (P<0.00001); I2 =97%
Test for overall effect: Z = 8.57 (P < 0.00001)
2 Pruritus
Frech 2008 45/67 5/134 5.5 % 18.00 [ 7.49, 43.23 ]
McKenzie 2007 27/30 15/29 25.2 % 1.74 [ 1.20, 2.52 ]
Subtotal (95% CI) 97 163 30.7 % 4.66 [ 3.25, 6.68 ]
Total events: 72 (Vaccine), 20 (Placebo)
Heterogeneity: Chi2 = 36.14, df = 1 (P<0.00001); I2 =97%
Test for overall effect: Z = 8.36 (P < 0.00001)
3 Vesicles
McKenzie 2007 5/30 0/29 0.8 % 10.65 [ 0.62, 184.25 ]
Subtotal (95% CI) 30 29 0.8 % 10.65 [ 0.62, 184.25 ]
Total events: 5 (Vaccine), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.63 (P = 0.10)
4 Skin discoloration
Frech 2008 5/67 0/134 0.6 % 21.84 [ 1.23, 389.17 ]
McKenzie 2007 16/30 2/29 3.4 % 7.73 [ 1.95, 30.69 ]
Subtotal (95% CI) 97 163 3.9 % 9.73 [ 2.87, 32.92 ]
Total events: 21 (Vaccine), 2 (Placebo)
Heterogeneity: Chi2 = 0.41, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 3.66 (P = 0.00025)
0.002 0.1 1 10 500
Favours Vaccine Favours Placebo
(Continued . . . )
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(. . . Continued)
Study or subgroup Vaccine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
5 Fever
Frech 2008 1/67 1/134 1.1 % 2.00 [ 0.13, 31.48 ]
Subtotal (95% CI) 67 134 1.1 % 2.00 [ 0.13, 31.48 ]
Total events: 1 (Vaccine), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.62)
6 Malaise
Frech 2008 5/67 9/134 9.9 % 1.11 [ 0.39, 3.19 ]
Subtotal (95% CI) 67 134 9.9 % 1.11 [ 0.39, 3.19 ]
Total events: 5 (Vaccine), 9 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
7 Headache
Frech 2008 9/67 14/134 15.4 % 1.29 [ 0.59, 2.82 ]
Subtotal (95% CI) 67 134 15.4 % 1.29 [ 0.59, 2.82 ]
Total events: 9 (Vaccine), 14 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
8 Diarrhoea
Frech 2008 9/67 12/134 13.2 % 1.50 [ 0.67, 3.38 ]
Subtotal (95% CI) 67 134 13.2 % 1.50 [ 0.67, 3.38 ]
Total events: 9 (Vaccine), 12 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.33)
Total (95% CI) 589 1054 100.0 % 3.87 [ 3.10, 4.84 ]
Total events: 195 (Vaccine), 73 (Placebo)
Heterogeneity: Chi2 = 70.40, df = 10 (P<0.00001); I2 =86%
Test for overall effect: Z = 11.87 (P < 0.00001)
Test for subgroup differences: Chi2 = 25.99, df = 7 (P = 0.00), I2 =73%
0.002 0.1 1 10 500
Favours Vaccine Favours Placebo
(1) Frech 2008: A natural challenge study in American adults travelling to Mexico and Guatemala.
(2) McKenzie 2007a: An artificial challenge study in healthy adult volunteers in the USA.
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Analysis 6.5. Comparison 6 Transcutaneous LT patch versus placebo, Outcome 5 Immunological response.
Review: Vaccines for preventing enterotoxigenic Escherichia coli (ETEC) diarrhoea
Comparison: 6 Transcutaneous LT patch versus placebo
Outcome: 5 Immunological response
Study or subgroup Vaccine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 > 4-fold increase in anti-LT specific IgA responses in serum/plasma
Frech 2008 (1) 49/60 2/110 71.2 % 44.92 [ 11.32, 178.27 ]
McKenzie 2007 (2) 25/27 0/20 28.8 % 38.25 [ 2.47, 593.01 ]
Subtotal (95% CI) 87 130 100.0 % 43.00 [ 12.33, 149.97 ]
Total events: 74 (Vaccine), 2 (Placebo)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 5.90 (P < 0.00001)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours Placebo Favours Vaccine
(1) Frech 2008: A natural challenge study in American adults travelling to Mexico and Guatemala.
(2) McKenzie 2007a: An artificial challenge study in healthy adult volunteers in the USA.
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Analysis 7.1. Comparison 7 Hyperimmune anti-E. coli CFA versus placebo, Outcome 1 All-cause diarrhoea.
Review: Vaccines for preventing enterotoxigenic Escherichia coli (ETEC) diarrhoea
Comparison: 7 Hyperimmune anti-E. coli CFA versus placebo
Outcome: 1 All-cause diarrhoea
Study or subgroup Vaccine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Freedman 1998 (1) 1/15 7/10 73.7 % 0.10 [ 0.01, 0.66 ]
Tacket 1999 (2) 5/10 3/10 26.3 % 1.67 [ 0.54, 5.17 ]
Total (95% CI) 25 20 100.0 % 0.51 [ 0.22, 1.15 ]
Total events: 6 (Vaccine), 10 (Placebo)
Heterogeneity: Chi2 = 7.10, df = 1 (P = 0.01); I2 =86%
Test for overall effect: Z = 1.62 (P = 0.11)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Vaccine Favours Placebo
(1) Freedman 1998: An artificial challenge study in adult volunteers in the USA
(2) Tacket 1999a: An artificial challenge study in adult volunteers in the USA
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Analysis 7.2. Comparison 7 Hyperimmune anti-E. coli CFA versus placebo, Outcome 2 Adverse events.
Review: Vaccines for preventing enterotoxigenic Escherichia coli (ETEC) diarrhoea
Comparison: 7 Hyperimmune anti-E. coli CFA versus placebo
Outcome: 2 Adverse events
Study or subgroup Vaccine Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Anorexia
Freedman 1998 (1) 1/15 6/10 0.11 [ 0.02, 0.79 ]
2 Malaise
Freedman 1998 1/15 3/10 0.22 [ 0.03, 1.85 ]
3 Gas
Freedman 1998 2/15 5/10 0.27 [ 0.06, 1.12 ]
4 Abdominal pain
Freedman 1998 2/15 10/10 0.16 [ 0.05, 0.51 ]
5 Headache
Freedman 1998 3/15 5/10 0.40 [ 0.12, 1.31 ]
0.01 0.1 1 10 100
Favours Vaccine Favours Placebo
(1) Freedman 1998: An artificial challenge study in adult volunteers in the USA
A D D I T I O N A L T A B L E S
Table 1. Currently available and experimental ETEC vaccines
Oral inactivated vaccines
• Cholera/rCTB - killed whole cell V. cholerae O1 (four strains, Classical and El Tor) with additional purified recombinant
cholera toxin B subunit. It is commercially available as Dukoral®, produced by SBL/Crucell, Sweden.
• ETEC-rCTB - killed whole cell ETEC (five strains expressing CFA/I,CS1-CS5).
• Colicin inactivated vaccine.
• Inactivated Shigella vector-ETEC vaccine expressing several ETEC antigens.
Oral live attenuated vaccines
• CFA/II toxin mutant formulation.
• Attenuated ETEC strains with gene deletion but with CFA/II antigen expression, Hola Vax, Cambridge Biostability Ltd,
Cambridge, UK.
• Attenuated Shigella vector-ETEC hybrid vaccine expressing the CFA/I CFs including the non-toxic mutated derivatives of LT.
• Attenuated V. cholerae vector-ETEC hybrid vaccines based on CVD 103-HgR or Peru-15 strains expressing several CFs
including the B subunit of CT.
• Attenuated S. typhi-ETEC hybrid vaccine expressing several ETEC antigens.
• ETEC vaccine based on attenuated Shigella flexneri hybrid constructs expressing CS3 and LTB/ST fusion toxin.
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Table 1. Currently available and experimental ETEC vaccines (Continued)
Other ETEC vaccines under development include
• Vaccine based on different ETEC fimbrial antigens.
• CF hyperexpression on ETEC strains.
• LT patch for transcutaneous immunization route.
• LT/CS6 patch for transcutaneous immunization route.
• DNA/vectored vaccine.
• Toxin conjugate vaccines.
• Edible plant derived LTB-based ETEC vaccine.
WC/rCTB: whole cell/recombinant cholera toxin B subunit; ETEC: enterotoxigenic E. coli; CFA: colonization factor antigen; CS: E.
coli surface antigen; LT: heat labile toxin; CT: cholera toxin; LTB/ST: heat labile toxin B subunit/heat stable toxin.
Table 2. Detailed Search Strategy
Search set CIDG SR¹ CENTRAL MEDLINE² EMBASE² LILACS²
1 E.coli Enterotoxigenic Es-
cherichia coli [MeSH]
Enterotoxigenic Es-
cherichia coli [MeSH]
Enterotoxigenic Es-
cherichia coli [Emtree]
E.coli
2 Enterotoxigenic ETEC ETEC ti, ab ETEC ti, ab Enterotoxigenic
3 ETEC Enterotoxigenic E coli Enterotoxigenic E coli
ti, ab
Enterotoxigenic E coli
ti, ab
ETEC
4 Travel* diarrh* Travel* diarrh* Travel* diarrh* ti, ab Traveller diarrhea
[Emtree]
Travel$ diarrh$
5 1 or 2 or 3 or 4 1 or 2 or 3 or 4 1 or 2 or 3 or 4 1 or 2 or 3 or 4 1 or 2 or 3 or 4
6 Vaccin* Vaccin* Vaccin* ti, ab Vaccin* ti, ab Vaccin$
7 5 and 6 5 and 6 5 and 6 5 and 6 5 and 6
8 Escherichia coli vaccines
[MeSH]
Escherichia coli vaccines
[MeSH]
Escherichia coli vaccine
[Emtree]
9 7 or 8 7 or 8 7 or 8
10 Limit 9 to humans Limit 9 to Human
¹Cochrane Infectious Diseases Group Specialized Register.
²Search terms used in combination with the search strategy for retrieving trials developed by The Cochrane Collaboration (Higgins
2008).
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Table 3. Characteristics of trials assessing clinical efficacy
Vaccine details Study ID Population details Challenge
Type Name Route Schedule Age Group Country set-
ting
Inactivated Cholera
WC-BS
Oral Three doses,
at 6 week in-
tervals
Clemens
1988
Children
aged 2 to 15
years
Women aged
> 15 years
Endemic Bangladesh Natural
Oral Two doses
two weeks
apart
Peltola 1991 Adults Travellers From Finland
to Morocco
Natural
Cholera
WC-rCTB
(Duko-
ral®)
Oral Two doses,
10 days apart
Scerpella
1995
Adults Travellers From USA to
Mexico
Natural
ETEC WC-
rCTB
Oral Two doses, 7
to 21 days
apart
Sack 2007 Adults Travellers From USA to
Mexico or
Guatemala
Natural
Oral Two doses, 7
to 21 days
apart
Wiedermann
2000
All ages Travellers From Austria
to LatinAmer-
ica, Africa, and
Asia.
Natural
Live attenu-
ated
CVD 103-
HgR
Oral Single dose Leyten 2005 Adults Travellers From Holland
to Indonesia,
Thailand, In-
dia, or West
Africa
Natural
PTL-003 Oral 2 doses, 10
days apart
McKenzie
2008
Adults Volunteers USA Artificial
Other Transcu-
taneous LT-
ETEC
patch
Patch 2 to 3 doses,
at 2 to 3 week
intervals
Frech 2008 Adults Travellers From USA
to Mexico and
Guatemala
Natural
Patch 2 to 3 doses,
at 2 to 3 week
intervals
McKenzie
2007
Adults Volunteers USA Artificial
Hyper im-
mune Anti-
E coli. CFA
Oral 3 times daily
for 5 to 7 days
Freedman
1998
Adults Volunteers USA Artificial
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Table 3. Characteristics of trials assessing clinical efficacy (Continued)
Oral 3 times daily
for 5 to 7 days
Tacket 1999 Adults Volunteers USA Artificial
WC = killed whole cell, BS = cholera toxin B subunit, rCTB = recombinant cholera toxin B subunit.
Table 4. Outcome definitions for primary and secondary measures of clinical efficacy
Vaccine Study ID Trial definitions Challenge type Confirmation of
ETEC
DIarrhoea Moderate or Severe
Diarrhoea
Cholera WC-BS Clemens 1988 ≥ 3 non-
bloody loose stools
in 24 hours, or fewer
episodes with signs
of dehydration
Se-
vere diarrhoea = ab-
sent or feeble pulse
plus one other sign
of dehydration
Natural Faecal culture
Peltola 1991 Any diarrhoea con-
firmed by the physi-
cian as abnormally
loose
Not reported. Natural Faecal culture
Cholera WC-
rCTB
(Dukoral®)
Scerpella 1995 ≥ 4unformed stools
in 24 hours, or ≥3
unformed stools in
8 hours, plus an
additional symptom
(nausea. pain, fever,
urgency, tenesmus)
Not reported. Natural Faecal culture
ETEC WC-rCTB Sack 2007 ≥
3 loose stools in 24
hours, plus at least
one other symptom,
such as abdominal
pain, cramps or nau-
sea
Severe diarrhoea =
≥ 5 loose stools
in 24 hours, or ill-
ness episodes with
abdominal cramps,
pain, or vomiting
that interfered with
daily activities
Natural Faecal culture
Wiedermann 2000: ≥ 3 liquid stools Not reported. Natural Faecal culture
CVD 103-HgR Leyten 2005 ≥ 3unformed stools
in 24 hours, or 2
unformed stools ac-
companied by vom-
iting, abdominal
cramps or subjective
Moderate diarrhoea
= 3 to 6 stools per
day
Severe diarrhoea =
≥ 6 stools per day
Natural Faecal culture
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Table 4. Outcome definitions for primary and secondary measures of clinical efficacy (Continued)
fever,
PTL-003 McKenzie 2008 1 loose stool weigh-
ing ≥ 300 g, or ≥
2 loose stools in 48
h with a combined
weight of ≥200 g,
Moderate diarrhoea
= 4 to 5 loose stools,
or 401 to 800 g of
loose stool, in 24
hours
Severe diarrhoea =
≥ 6 loose stools, or >
800 g of loose stools,
in 24 hours
Or mild diarrhoea
plus one of these
symptoms rated as
moderate or severe:
nausea,
vomiting, anorexia,
abdominal pain, or
cramps
Artificial Assumed all
Transcutaneous
LT-ETEC patch
Frech 2008 ≥ 3 loose stools in
24 hours
Moderate diarrhoea
= 4 to 5 loose stools
Severe diarrhoea = 6
or more loose stools
Natural Faecal culture
McKenzie 2007 1 loose stool weigh-
ing ≥ 300 g or
≥ 2 loose stools in
48 hours weighing
a total of ≥200 g,
within 120 hours af-
ter challenge
Moderate/severe di-
arrhoea = > 400 g
of loose stool in 24
hours, or ≥ 4 loose
stools in 24 hours,
or ≥ 2 loose stools
within a 48 hour
period totaling ≥
200 g, or a single
loose stool weighing
≥ 300 g plus one of
the following symp-
toms rated as mod-
erate or severe: nau-
sea, vomiting, ab-
dominal pain, or
cramps
Artificial Assumed all
Hyperimmune
Anti-E coli. CFA
Freedman 1998 1 liquid stool of ≥
300 mL or 2 liquid
stools totaling > 200
mL during any 48
hour period within
120hours after chal-
Not reported. Artificial Assumed all
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Table 4. Outcome definitions for primary and secondary measures of clinical efficacy (Continued)
lenge
Tacket 1999 1 diarrhoeal stool of
> 300 mL or 2 di-
arrhoeal stools total-
ing > 200mL passed
during a 48 hour pe-
riodwithin 96hours
after challenge
Not reported. Artificial Assumed all
Table 5. Additional immunological data for responses to CFs in the IgA isotype to ETEC WC-rCTB vaccine
Study
ID
Age
group
Trial
setting
Number of participants with a > 2-fold increase in immunological response after the second dose
of oral ETEC-rCTB (%)
CFA/I CS1 CS2 CS3 CS4 Re-
marks
V P V P V P V P V P
Savarino
1998
Adults Egypt 15/16
(94%)
4/16
(25%)
11/16
(69%)
1/16
(6%)
13/16
(81%)
2/16
(13%)
ND ND 16/16
(100%)
6/16
(38%)
Serum
Cohen
2000
(Study
2)
Adults Israel 9/35
(26%)
1/40
(3%)
11/35
(31%)
2/40
(5%)
ND ND ND ND ND ND Serum
Jert-
born
2001
Adults Swe-
den
16/19
(84%)
0/12
(0%)
4/19
(21%)
1/12
(8%)
10/19
(53%)
0/12
(0%)
ND ND 12/19
(63%)
0/12
(0%)
Serum
Hall
2001
(Study
1)
Adults Egypt 26/38
(68%)
2/35
(6%)
21/38
(56%)
0/35
(0%)
12/38
(31%)
2/35
(6%)
ND ND 26/38
(69%)
4/35
(12%)
Serum
Savarino
1999
(Study
1)
Chil-
dren
6-12 Y
Egypt 16/16
(100%)
2/16
(13%)
3/8
(38%)
1/9
(11%)
12/13
(92%)
2/12
(17%)
ND ND 14/15
(93%)
4/16
(25%)
ASC
Hall
2001
(Study
2)
Chil-
dren
6-12 Y
Egypt 49/51
(96%)
6/54
(11%)
47/51
(92%)
4/54
(7%)
40/51
(78%)
5/54
(9%)
ND ND 43/51
(84%)
3/54
(6%)
Serum
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Table 5. Additional immunological data for responses to CFs in the IgA isotype to ETEC WC-rCTB vaccine (Continued)
Savarino
1999
(Study
2)
Chil-
dren
2-5 Y
Egypt 18/19
(95%)
1/10
(10%)
ND ND 15/18
(83%)
1/10
(10%)
ND ND ND ND ASC
Hall
2001
(Study
3)
Chil-
dren
2-5 Y
Egypt 41/47
(87%)
5/46
(11%)
43/47
(91%)
1/46
(2%)
37/47
(79%)
6/46
(12%)
ND ND 33/47
(70%)
3/46
(7%)
Serum
Qadri
2003
Chil-
dren
18-36
M
Bangladesh
58/79
(73%)
13/79
(16%)
61/79
(77%)
10/79
(13%)
69/79
(87%)
8/79
(10%)
ND ND 55/79
(70%)
2/79
(3%)
Plasma
Savarino
2002
Chil-
dren
6-18
M
Egypt 22/36
(61%)
5/28
(18%)
7/36
(20%)
1/28
(4%)
9/36
(26%)
1/28
(4%)
ND ND 14/36
(39%)
2/28
(7%)
Serum
Qadri
2006a
Chil-
dren
6-17
M
Bangladesh
47/79
(59%)
4/79
(5%)
53/79
(67%)
26/79
(33%)
37/79
(47%)
16/79
(20%)
40/79
(50%)
12/79
(15%)
ND ND Plasma
V = vaccine, P = placebo, CS = colonization surface antigen, ND = not done , ASC = antibody secreting cell, CFA = colonization factor
antibody
Table 6. Additional immunological data for IgA response to CFs to live oral attenuated vaccine
Study ID Number of participants with > 2-fold increase in immunological response (%)
CS1 CS2 CS3 CS4 Remarks
V P V P V P V P
McKenzie
2008
7/17
(41%)
1/16
(6%)
ND ND 7/17
(41%)
0/16
(0%)
ND ND Serum
V = vaccine, P = placebo, CS = colonization surface antigen, ND = not done
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Since the publication of the original review, several changes have occurred in standard Cochrane methodology which were not in the
original review. Notably, the method of assessing risk of bias has changed, and summary of findings tables incorporating the GRADE
methodology for assessing the quality of evidence have been added. We have described the methodology for these additions in the
methods section.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Cholera Toxin [adverse effects; immunology]; Cholera Vaccines [adverse effects; ∗therapeutic use]; Developing Countries; Diarrhea
[microbiology; ∗prevention & control]; Enterotoxigenic Escherichia coli [∗immunology]; Randomized Controlled Trials as Topic;
Travel; Vaccines, Inactivated [adverse effects; therapeutic use]
MeSH check words
Adult; Child; Humans
93Vaccines for preventing enterotoxigenic Escherichia coli (ETEC) diarrhoea (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
